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Rapidly proliferating cancer cells have increased biosynthetic and bioenergetic needs 
compared to quiescent cells. Hence, they undergo a reprogramming of intermediary metabolism, 
mainly by upregulating the uptake and catabolism of certain nutrients. The classical example of 
this is the ‘Warburg effect’ or aerobic glycolysis, defined as an increase in glucose uptake 
coupled to lactate secretion, regardless of oxygen availability in cancer cells. One consequence 
of this is that the majority of glucose carbon is diverted away from the mitochondria and the 
tricarboxylic acid (TCA) cycle, and secreted out of the cell as lactate. This prompts some cancer 
cells to exhibit an increased dependence on glutamine metabolism to refill the TCA cycle. 
However, recent studies have uncovered widespread heterogeneity on the roles of glucose and 
glutamine metabolism in cancer cells, prompting a need for further clarification.  
In order to examine these metabolic pathways in cancer cells, I first helped develop high-
resolution LC-MS metabolomic workflows. The initial objective of my thesis focused on the 
Warburg effect, and specifically, the increased rate of glycolytic flux that occurs in colon cancer 
cells. I demonstrated that changes in glycolytic flux could modify specific histone acylation 
marks in a dose-dependent manner, suggesting that a possible function of the Warburg effect is 
to confer specific signaling effects on cancer cells.  
The second objective of my thesis focused on defining the contribution of the 
mitochondrial glutaminase isoenzyme GLS2 on the observed variability in glutamine 
 dependence in various breast cancer cell types. I identified GLS2 as an important metabolically 
active enzyme in breast cancer cells that can feed TCA cycle anaplerosis. This finding has 
important clinical implications due to the fact that a glutaminase inhibitor, which fails to block 
GLS2 activity, is currently in Phase II trials.  
In summary, my dissertation work further contributes to our fundamental understanding 
of the metabolic programs operating in cancer cells, by uncovering novel aspects of both glucose 
and glutamine metabolism. This work identifies new underlying causes of the metabolic 
heterogeneity observed in cancer cells and may prove relevant to future improvements in cancer 
therapies. 
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Chapter 1 
 
*Overview 
 
Introduction 
Cancer cells undergo a reprogramming of metabolism in order to maintain bioenergetics, redox 
status, cell signaling and biosynthesis, in what is often a poorly vascularized, nutrient-deprived 
microenvironment [1-4]. To supply biosynthetic pathways with precursors, the uptake and 
catabolism of certain nutrients are upregulated in tumor cells. For example, the ‘Warburg effect’, 
also known as aerobic glycolysis, is a phenomenon of increased glucose uptake coupled to 
lactate secretion, regardless of oxygen availability in cancer cells. This unique metabolic feature 
occurs in many human tumors, such that positron emission tomography (PET) using the glucose 
analog 18F-flurodeoxyglucose is widely used for imaging tumors in the clinic [1, 5]. One 
consequence of the Warburg effect is that the majority of glucose carbon is diverted away from 
the mitochondria and the tricarboxylic acid (TCA) cycle, and secreted out of the cell as lactate, 
forcing the cell to find alternative sources to compensate for this. Correspondingly, many cancer 
cells display a dependence on an exogenous supply of glutamine; despite it being a non-essential 
amino acid (NEAA) that mammalian cells can synthesize de novo (Figure 1.1). However, beyond 
serving as a source of carbon to replenish the TCA cycle, glutamine also serves as an important 
source of reduced nitrogen for biosynthetic reactions, as well as a precursor to glutathione, 
nucleotides and lipid synthesis via reductive carboxylation (Figure 1.2) [1, 2, 6, 7]. Indeed, an 
inhibitor of the mitochondrial enzyme glutaminase, which converts glutamine to glutamate, a  
                                                
* Adapted from Cluntun, A.A., et al. (2017) Trends in Cancer. 3(3): p. 169-180. 
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Figure 1.1. The Warburg effect and TCA cycle anaplerosis.  
The majority of glycolytic carbons are diverted away from the mitochondria and secreted as 
lactate. Glutamine metabolism can be utilized as an anaplerotic source of carbon to maintain the 
TCA cycle. Gln: Glutamine, Glu: Glutamate, α−ΚG: alpha-ketoglutatarate, TCA: Tricarboxylic 
acid cycle.  
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precursor of the TCA cycle intermediate α-ketoglutarate (α-KG), is currently being evaluated in 
clinical trials for treatment of a range of malignancies [8-12]. Several recent studies have led to 
new insights in our understanding of the roles of both glucose and glutamine metabolism in 
cancer. For example, a recent study found that neither glucose nor glutamine is the source of the 
majority of cell mass in proliferating mammalian cells[13]. This was a counterintuitive finding as 
both glucose and glutamine have the highest consumption rates in these cells and yet non-
glutamine amino acids, consumed at much slower rates, were determined to provide abundant 
carbon and nitrogen to these cells. Another important study revealed significant heterogeneity in 
glucose metabolism between patients and within individual lung tumors[14]. However, 
glutamine metabolism, in particular, has had a series of recent reports that has cast some doubt 
and confusion on its importance in cancer cells. In particular, a recent study found that the 
requirements for glutamine undergo changes upon transition from monolayer culture to 
anchorage-independent culture [7], and another study suggested that glutamine catabolism was 
not required for tumorigenesis in vivo in some mouse models, which led to the conclusion that 
glutamine metabolism may not have a role in cancer [15]. Nevertheless, numerous other studies 
have provided compelling evidence that a requirement for glutamine catabolism indeed exists in 
many in vivo settings [10, 16-23]. Here I will discuss these seemingly contradictory recent 
findings in detail and explain the factors underlying the heterogeneity of glutamine metabolism 
in cancer.    
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Figure 1.2. The glutamine metabolic footprint in cancer. 
Glutamine has a five-carbon backbone and two nitrogen atoms (α and γ) to donate. Glutamine’s 
metabolic footprint goes well beyond TCA cycle anaplerosis. Gln: Glutamine, Glu: Glutamate, 
GSH: Glutathione, Asp: Aspartate, Ala: Alanine, Thr: Threonine, Gly: Glycine, Ser: Serine, Cys: 
Cysteine, Pro: Proline, Mal: Malate, Pyr: Pyruvate, Lac: Lactate, OAA: Oxaloacetate, Cit: 
Citrate, TCA: Citric acid cycle, α-KG: alpha-ketoglutarate. 
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Culture conditions and model systems influence glutamine metabolism 
The ability to culture cell lines derived from human tumors has, over the past 60 years, 
provided researchers with a powerful tool for studying cancer biology. A common characteristic 
of mammalian cell lines grown in culture, noted by Harry Eagle in the 1950s [24], is a 
dependence on an abundant exogenous supply of the NEAA glutamine. After glucose, glutamine 
is the most rapidly consumed nutrient by many human cancer cell lines grown in culture [13, 25]. 
However, glutamine requirements are very heterogeneous among different cancer cell lines, 
ranging from those that are glutamine auxotrophs, to those that can survive and proliferate in the 
absence of an exogenous glutamine supply [20, 26]. Recent studies have demonstrated that the 
tissue of origin, the underlying genetics, and the microenvironment, can all impact cancer cell 
metabolism, including utilization of glutamine. Importantly, tumor microenvironment conditions 
can be modeled ex vivo, as the constituents of the culture media can be customized and other 
essential variables that determine metabolic requirements such as oxygen levels can be 
controlled [27, 28]. 
In monolayer culture, the non-small cell lung cancer (NSCLC) cell line H460 shows 
abundant uptake of glutamine, which is primarily utilized for TCA cycle anaplerosis. However, 
when the same cells are grown under anchorage-independent conditions as tumor spheroids, 
glutamine oxidation is suppressed and instead reductive glutamine metabolism via cytosolic 
isocitrate dehydrogenase 1 (IDH1) occurs [7]. The isocitrate/citrate generated by IDH1 then 
enters the mitochondria and undergoes oxidative metabolism via IDH2, generating mitochondrial 
NADPH to mitigate the elevated reactive oxygen species (ROS) levels that occur during 
anchorage-independent growth. 
Distinct metabolic alterations take place when NSCLC cells are transitioned from an ex 
  8 
vivo to an in vivo environment. When cells derived from mutant KRAS-driven NSCLC tumors 
are grown in culture, glutamine supplies the TCA cycle with carbon, and inhibition of the 
mitochondrial enzyme glutaminase (GLS) suppresses cell proliferation [15]. However, this 
glutamine-dependent phenotype is lost when the same cells are grown as lung tumors in mice. 
Instead, TCA cycle intermediates in the tumors are derived primarily from glucose via glycolysis 
and the enzyme pyruvate carboxylase (PC), and tumors are resistant to glutaminase inhibition or 
to CRISPR/Cas9-mediated GLS deletion [15]. At first glance, these findings may seem surprising 
and contradictory to previous reports regarding the importance of glutamine metabolism in 
cancer cells both ex vivo and in vivo (see Table 1). However, they are consistent with earlier 
studies showing that some NSCLC tumors in human patients rely on glucose-derived carbon and 
PC activity, and show upregulated PC gene expression [29]. Indeed, PC has been identified as an 
essential factor in cancer cells that display glutamine-independent growth [30]. Nevertheless, 
many tumors rely on glutamine-mediated TCA cycle anaplerosis in vivo with concordance of 
glutamine dependence ex vivo and in vivo. (see Table 1), as discussed in detail below [9, 10, 12, 
16, 17, 31] (Figure 1.3). Thus, recent observations in certain NSCLC mouse tumors cannot be 
generalized to other cancers.      
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Figure 1.3. TCA cycle anaplerotic fluxes affect glutaminase inhibition efficacy. 
There are two main anaplerotic fluxes that can feed the citric acid cycle, a glutamine flux via 
glutaminase (GLS and/or GLS2) and a glucose flux via pyruvate carboxylase (PC). Glutamine 
synthetase (GLUL) is also an important enzyme for this process as it can synthesize glutamine 
from glutamate and thus allow cells to survive in glutamine-depleted conditions. The expression 
levels of these enzymes vary according to tissue type and can greatly affect their sensitivity to 
glutaminase inhibition. GBM: Glioblastoma, NSCLC: non-small cell lung carcinoma, Pyr: 
Pyruvate, Lac: Lactate, Cit: Citrate, TCA: Citric acid cycle, α-KG: alpha-ketoglutarate. 
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Table 1.1. Glutaminase inhibition across different cancer types ex vivo and in vivo. 
Tumor type GLS inhibition Experimental Models 
ex vivo in vivo 
NSCLC 
(Lung) 
Sensitive Resistant GEMs and xenografts  
GBM Resistant Resistant Patient derived 
xenografts 
Kidney  Sensitive Transgenic MYC 
Mice 
Liver  Sensitive Transgenic mice 
Breast 
(luminal) 
Resistant   
Breast (Basal) Sensitive Sensitive xenografts 
T cell ALL Sensitive Sensitive NOTCH1-induced T-
ALL mice 
Prostate Sensitive 
(+metformin) 
Sensitive 
(+metformin) 
Transgenic (TRAMP) 
mice 
Pancreas Sensitive, 
sensitizes cells to 
β-lap treatment  
Sensitive, sensitizes 
cells to β-lap 
treatment 
KRAS induced PDAC 
xenografts, β-
lapachone (β-lap) 
Fibrosarcoma Sensitive 
(+IKKβ) 
Sensitive 
(+IKKβ) 
xenografts, IκB kinase 
β (ΙΚΚβ) 
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Metabolic phenotype varies with cancer subtype and microenvironment 
Different mammalian organs exhibit distinct modes of glutamine metabolism. For 
example, the kidney mediates net glutamine catabolism, generating ammonia for pH homeostasis 
and supplying carbon for renal gluconeogenesis [32], whereas lung, skeletal muscle, and adipose 
tissues exhibit net de novo glutamine synthesis via the enzyme glutamine synthetase (GLUL) 
[33]. Similarly, human tumors show a range of metabolic phenotypes that vary with the tissue of 
origin, the cancer subtype, and the tumor microenvironment.  
Although mammalian cells can synthesize glutamine de novo using GLUL [34], some 
cancer cells do not express high levels of GLUL and instead are dependent on an exogenous 
supply of glutamine, which can be catabolized in mitochondria via GLS. There is strong 
evidence that GLS plays an important role in the development of a range of cancers in vivo. 
While data in The Cancer Genome Atlas (TCGA) indicate that the GLS transcript is 
downregulated relative to surrounding healthy tissue in NSCLC, consistent with the studies 
described above, GLS mRNA levels are frequently upregulated in several other human 
malignancies (Figure 1.2.). These include tumors of the colon, esophagus, liver, stomach, 
thyroid, as well as head and neck cancer. In conditional transgenic mouse models, 
overexpression of the MYC proto-oncogene in kidney or liver results in the formation of tumors 
in which GLS levels are highly upregulated relative to the surrounding healthy tissue [16, 17]. In 
both of these animal models, inhibition of GLS impedes tumor progression, and deletion of one 
GLS allele in the liver model significantly delays early tumor progression. 
In contrast, glutamine synthesis is upregulated in some cancers. As outlined above, GLS 
is dispensable for growth of NSCLC tumors in vivo [15], and NSCLC tumors can actually 
accumulate newly synthesized glutamine [35]. Similarly, some human glioblastoma (GBM) 
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tumors do not significantly catabolize glutamine via GLS and the TCA cycle, but instead 
accumulate large pools of glutamine, synthesized by GLUL from glucose-derived carbon [36]. 
This glutamine feeds de novo purine biosynthesis, and renders GBM cells self-sufficient for 
glutamine requirements [34]. Consistent with this metabolic phenotype, GLUL and PC are 
expressed in most GBM tumors, whereas GLS expression is downregulated relative to 
surrounding brain tissue [34, 36]. 
Even among tumors that arise in a specific organ, different cancer subtypes can show 
distinct patterns of glutamine metabolism. Luminal breast cancers frequently exhibit high GLUL 
and low GLS expression, whereas the opposite is true of basal breast cancers [19]. Matching 
these expression patterns, most luminal breast cancer cells can be cultured in glutamine-free 
media, whereas basal cells are highly sensitive to glutamine withdrawal and to inhibition of GLS, 
both in cell culture and when grown as xenograft tumors in vivo [10, 19]. Metabolic 
heterogeneity can also arise between different regions of the same tumor. For example, highly 
perfused regions of NSCLC tumors oxidize diverse nutrients to fuel the TCA cycle, whereas less 
perfused regions primarily utilize glucose-derived carbon [14].  
Thus, some tumors that arise in some tissues are typically dependent on glutamine 
anaplerosis, whereas NSCLC and GBM more frequently rely on pyruvate anaplerosis to maintain 
TCA cycle flux (Figure 1.2.). A recent study using the mouse breast cancer cell line 4T1, which 
metastasizes to the lung with nearly 100% penetrance within a time frame of a day, sheds some 
light on the factors that influence choice of anaplerotic substrate. In contrast to primary breast 
tumors, lung metastases were found to rely on PC for TCA cycle anaplerosis, indicating that the 
tissue microenvironment might favor one metabolic phenotype over another [37]. Supporting this 
notion, the pyruvate/glutamine ratio is approximately 3-fold higher in the interstitial fluid of the 
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lungs than in blood plasma, and the pyruvate concentration and expression level of PC in breast 
cancer lung metastases are elevated relative to primary breast tumors [37]. When cultured ex 
vivo, cell lines established from the lung metastases reverted to low levels of PC-dependent 
anaplerosis, similar to the parental cell line, again illustrating the effect of environment on 
metabolic phenotype [38]. Nevertheless, cell lines established from 4T1 metastases in different 
organs do retain some distinctions in their gene expression and metabolic profiles, indicating that 
adaptation to the microenvironmental nutrient supply does not fully explain the metabolic 
reprogramming that occurs during metastasis [38]. Another factor that may alter metabolism in 
the tumor microenvironment is the state of the immune compartment in the tumor. Recent 
reports have shown that cancer cells can compete with T cells for glucose within the tumor 
microenvironment and the resulting glucose limitation in T cells suppresses anti-tumor 
immunity[39, 40]. Given that glutamine metabolism is an important requirement for the 
metabolism of immune cells (i.e. Immunometabolism)[41-43] a similar effect may occur due to 
competition for glutamine within the microenvironment. 
 
The impact of oncogenes on glutamine metabolism 
Tumors that arise in different organs, but from the same genetic lesion can also have 
distinct phenotypes for glutamine metabolism. One study demonstrated that MYC-induced liver 
tumors exhibit elevated glutamine catabolism, with increased GLS expression and suppressed 
GLUL expression relative to surrounding tissue [17, 35]. In contrast, MYC-induced NSCLC 
tumors exhibit increased expression of GLUL, and accumulate glutamine [35]. c-Myc can 
regulate the expression of both GLS and GLUL through mechanisms involving suppression of 
miRNA-23a/b in the case of GLS, or upregulation of thymine DNA glycosylase, which leads to 
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demethylation of, and increased expression from, the GLUL gene promoter [44, 45]. These 
mechanisms serve as examples to potentially explain, albeit non-exhaustively, why c-Myc has 
contrasting effects on glutamine metabolism in different cellular contexts. Tumors arising within 
the same tissue, but driven by different oncogenes, can also be metabolically divergent. In 
contrast to MYC-induced liver tumors, MET-induced liver tumors lose GLS expression, and 
overexpress GLUL and accumulate glutamine [35]. Furthermore, there are many other factors 
that can regulate glutamine metabolism such as the activity of c-Jun[46], Rb[47, 48], PGC-
1/ERRα [49], GLUL acetylation levels [50] and others[4, 6]. Thus, the metabolic phenotype of a 
given cancer seems to be determined by three key parameters: the tissue of origin, the underlying 
genetic factors driving tumorigenesis, and the microenvironment. 
 
Tumor glutamine supply 
Glutamine can be imported from the microenvironment by the solute carrier (SLC) group 
of transporters, including members of the SLC1, SLC6, SLC7, SLC36, and SLC38 families. The 
Na+/amino acid exchanger SLC1A5 and the unidirectional Na+/Cl-/amino acid symporter 
SLC6A14 are both regulated by c-Myc, and are overexpressed in several cancers [51]. Certain 
tumors such as pancreatic ductal adenocarcinoma (PDAC) are typically poorly vascularized, and 
consequently do not have an abundant serum supply of glutamine [52]. PDAC cells instead can 
in some cases use macropinocytosis to engulf extracellular proteins, which are then degraded in 
lysosomes to release glutamine and other amino acids [52-55]. An alternative route for cancer 
cell glutamine supply involves delivery of amino acids via extracellular vesicles shed by 
neighboring cells into the tumor microenvironment. Both PDAC and prostate cancer cells can 
grow in nutrient-deprived conditions when supplied with amino acids by exosomes shed by 
  16 
cancer-associated fibroblasts (CAFs) [56]. Additionally, recent work using ovarian carcinoma 
mouse models uncovered a reliance of cancer cells on stromal CAFs to maintain growth when 
glutamine is scarce. These fibroblasts boost glutamine synthesis from atypical sources to feed 
adjacent cancer cells [57]. Nevertheless, tumors that utilize macropinocytosis or uptake 
extracellular vesicles to acquire glutamine may still require glutaminase and exhibit sensitivity to 
its inhibition[20, 58].  
 
The metabolic fate of glutamate in cancer   
The first step of glutamine catabolism is its conversion to glutamate, which is catalyzed 
by cytosolic glutamine amidotransferases or by mitochondrial glutaminases. Glutamine-derived 
glutamate has diverse fates in proliferating cells, including consumption during protein synthesis, 
supplying nitrogen for transamination reactions, secretion from the cell in exchange for other 
nutrients, incorporation into the antioxidant tripeptide glutathione, and conversion into α-KG for 
TCA cycle anaplerosis. Formation of α-KG is catalyzed by the glutamate dehydrogenases 
(GLUD1/2), which release ammonia as a byproduct, or by transaminases, which transfer the 
amine-nitrogen of glutamate onto an α-keto acid to generate another amino acid. Some breast 
cancer cells are known to catabolize glutamate primarily via transaminases, thus conserving the 
amine nitrogen [59]. Alanine transaminase 2 (GPT2), in particular, is critical for α-KG 
generation and therefore for glutamine/glutamate-mediated TCA cycle anaplerosis in colon 
cancer cells [60, 61]. In contrast to proliferative cells, transaminase expression is low in 
quiescent cells, and instead GLUD expression is induced [62]. 
Another major fate of glutamine-derived glutamate is efflux from the cell, and glutamine 
consumption is closely mirrored by glutamate release across the NCI-60 panel of cell lines [25]. 
  17 
The transporter SLC7A11 mediates exchange of intracellular glutamate for extracellular cystine, 
which, once inside the cell, is reduced to cysteine, the rate-limiting amino acid for glutathione 
biosynthesis [51]. Expression of the SLC7A11 gene is induced by c-Myc, and is upregulated in a 
number of cancers [24]. In addition to the important role of cystine import for redox 
homeostasis, in some tumors the secreted glutamate can stimulate proliferation by acting on 
metabotropic and ionotropic glutamate receptors [51].  
 
Epigenetics and signaling 
Underlying some of the connections between tumor tissue-of-origin, microenvironment, 
and metabolic phenotype, is the tumor epigenetic landscape. The connection between 
metabolism and epigenetics has been better appreciated in recent years [63, 64]. Glucose 
metabolism, as I will discuss in more detail in the next chapter, has been connected to many 
epigenetic and posttranslational modifications (PTMs), such as histone and protein acetylation, 
DNA and histone methylation and many other PTMs. However, given the importance of 
glutamine in various crucial metabolic pathways, it is not surprising that it is also an important 
link between metabolism and various epigenetic and post-translational marks. Many epigenetic 
modifications and processes are regulated by glutamine-derived metabolites including α-KG, 
which is a cofactor for Jumonji-domain-containing histone demethylases [63]. In a variety of 
xenograft tumors, the poorly vascularized tumor core shows a selective deficiency of glutamine 
relative to other amino acids, and a corresponding depletion of glutamine-derived α-KG [27]. 
This results in an inhibition of α-KG-dependent histone demethylation of H3K27 loci by a 
Jumonji-domain containing histone demethylase. Consequently, the tumor core exhibits 
pronounced histone hypermethylation, leading to suppressed expression of differentiation-related 
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genes and cancer cell dedifferentiation. Additionally, downstream metabolites such as succinate, 
fumarate and the oncometabolite 2-hydroxyglutarate (2-HG), which arises from mutated 
isocitrate dehydrogenase 1/2 (IDH1/2) in gliomas and acute myeloid leukemias, can all inhibit 
these same demethylases [65]. Interestingly, a recent study found that histone hypermethylation 
can be induced in V600EBRAF melanoma cells by withdrawing glutamine, and the consequent 
changes in gene expression lead to resistance to BRAF inhibitor treatment [27]. This mechanistic 
link between glutamine levels and gene-regulatory chromatin changes has important implications 
for the development of targeted cancer treatments. Inhibition of GLS is currently being evaluated 
in clinical trials (see below), and might be expected to trigger a histone hypermethylation 
phenotype that can lead to drug resistance following depletion of glutamine-derived α-KG. 
Although this suggests a possible mode of resistance to GLS-targeted therapies, it also points 
towards potential drug synergies that could be exploited in combination treatments. For example, 
the drug metformin has been identified to have a profound impact on fuel dependence in cancer 
cells, as it can decrease glucose oxidation and increase glutamine dependency in prostate cancers 
both ex vivo and in vivo [21, 28]. Furthermore, glutamine can contribute to the intracellular 
acetyl-CoA pool as well as to NAD/NADH levels, suggesting a potential role in regulating 
histone and protein acetylation levels and patterns. Moreover, it has also been shown that UDP-
glucosamine (UDP-GlcNAc), used for N-acetylglucosamination (GlcNAcylation) of histones 
and proteins and can regulate gene expression [66], can be synthesized from glutamine and can 
also be modulated by it through hexosamine biosynthesis via mTORC2 [67, 68].  
Additionally, glutathione (GSH) can inhibit the activity of S-adenosyl methionine 
synthetase (MAT1A), a key enzyme in the synthesis of S-adenosyl methionine (SAM), the main 
methyl donor in the cell [69]. It has recently been reported that histone H3 can be S-
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glutathionated on Cyc110, which can cause changes in nucleosome stability and alter chromatin 
structure. Interestingly this modification was observed to increase in proliferating cells relative to 
quiescent cells [70] Together, this indicates a critical role for glutamine metabolism in regulating 
and controlling a wide array of epigenetic and PTM marks.  
 In addition to influencing gene expression via epigenetic mechanisms, recent work has 
implicated glutamine as a signaling agent that can promote cancer progression independently of 
its metabolic role. As an example, extracellular glutamine was recently shown to activate the 
transcription factor STAT3 to promote cancer cell proliferation [71]. Intracellular glutamine as 
well can stimulate cell signaling pathways, indirectly activating the mechanistic target of 
rapamycin complex 1 (mTORC1) [72]. Furthermore, efflux of intracellular glutamine via 
SLC7A5 can drive leucine uptake, another amino acid that is required for mTORC1 activation 
[73]. Recent work has also connected glutamine metabolism to NOTCH signaling in acute 
lymphoblastic leukemia (ALL). Inhibiting glutaminolysis and autophagy synergistically 
enhances the antileukemic effects of anti-NOTCH1 therapies, providing another example of the 
importance of glutamine metabolism in vivo [18]. 
 
Targeting glutamine metabolism for cancer therapy 
The diverse roles played by glutamine in proliferating cells, supplying carbon and reduced 
nitrogen for biosynthetic reactions and redox homeostasis, present opportunities for targeting 
glutamine metabolism for cancer therapy [74]. A number of approaches are conceivable, 
including depletion of glutamine in blood serum, blockade of cellular glutamine uptake, and 
inhibition of enzymes involved in glutamine synthesis or catabolism [62]. L-asparaginases, 
which are routinely used to treat ALL patients, catalyze the deamidation of both asparagine and 
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glutamine, leading to depletion of both of these amino acids in serum [75]. Since most ALL cells 
are auxotrophic for asparagine, L-asparaginase effectively starves them of this nutrient. The 
glutamine hydrolysis activity of L-asparaginases is also thought to contribute to their 
cytotoxicity, in part because glutamine is required for de novo synthesis of asparagine by 
asparagine synthetase, one potential resistance mechanism to asparagine starvation [75]. 
Early clinical trials of glutamine antimetabolites revealed unacceptable systemic toxicity, 
indicating that more selective approaches, for example by defining the tumors that might respond 
to lower doses, are required to disrupt glutamine metabolism in cancer patients [76]. Two classes 
of GLS inhibitors have been identified, based on the lead compound molecules ‘968’ and BPTES 
[11, 12]. The only potential drug to progress beyond preclinical studies, to our knowledge, is the 
inhibitor CB-839, which is currently being evaluated in Phase I clinical trials [8]. CB-839 is 
based on the BPTES scaffold, has an IC50 value against recombinant human GLS of <50 nM 
[10], and has shown efficacy against cultured cancer cell lines and xenograft models for triple-
negative breast cancer and multiple myeloma [9, 10, 59]. Consistent with studies showing that 
GLS-mediated glutamine catabolism is required for in vivo growth of some tumor types but not 
others, only certain cancers are sensitive to GLS inhibition, and selection of appropriate target 
patient groups for CB-839 treatment is essential [8]. Efforts to develop small-molecule inhibitors 
of the GLS2 isozyme have been limited, presumably because of the conflicting literature reports 
concerning the importance of this enzyme in cancer. However, lead compounds with sub-
micromolar IC50 values against recombinant GLS2 were recently identified, and inhibit growth 
of liver and lung cancer cell lines [77]. It remains to be seen whether GLS2 could be targeted for 
treatment of tumors such as neuroblastoma, which frequently exhibit elevated GLS2 expression 
downstream of N-Myc. 
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A number of other nodes of cellular glutamine/glutamate metabolism have been proposed 
as attractive targets for cancer therapy, including transaminases [78], glutamine and glutamate 
transporters [51], asparagine synthetase [79], and glutamate dehydrogenase [80]. However, to 
date, studies remain preclinical and there is a lack of potent and selective inhibitors of these 
proteins, although each of these targets has scientific promise[74].  
 
Concluding Remarks  
Our understanding of the roles played by glutamine in cancer is evolving rapidly, and 
recent work has provided new insights and also has raised a number of questions. It is now clear 
that there is a not a single ‘metabolic map’ or ‘metabolic switch’ describing cancer cell 
metabolism [81], and the fate of glutamine varies with a range of parameters, including the tissue 
of origin of a cancer, the genetic aberrations which drive it, the tumor microenvironment, and 
possibly diet and host metabolism. The collective effect of these variables is striking, such that 
the metabolic phenotypes of cancer cells range from those that are highly dependent on 
catabolism of exogenous glutamine, to those that accumulate glutamine via de novo synthesis 
and are self-sufficient for glutamine requirements. Adding an additional level of complexity, 
recent studies have demonstrated that metabolic phenotype can change when cancer cells are 
transitioned between different culture systems, or between ex vivo cell culture and in vivo animal 
model environments. Standard cell culture media contain excesses of certain nutrients relative to 
their physiological concentrations, while completely lacking other nutrients such as acetate or 
aspartate which can play important roles in tumor metabolism [82]. However, these variables are 
controllable, and we anticipate that future studies will further characterize how metabolic 
phenotype responds to changing nutrient availability. We also anticipate that advances in 
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metabolic labeling and modeling methods [37, 83-87], as well as the development of subcellular 
compartment-specific metabolite isolation methods [88], will reveal new insights into the 
compartmentalization of glutamine metabolism in cancer cells. 
Although the glutamine dependence of some NSCLC cells is lost when they are grown in 
vivo, the canonical anaplerotic role of glutamine prevails in other contexts in vivo [9, 10, 12, 16-
18, 31], and clinical trials of the GLS inhibitor CB-839 have yielded some promising results [8] 
suggesting that these recent observations in NSCLC models is certainly not general to all 
cancers. It is also important to note that the dispensability of glutamine in certain circumstances 
does not imply that anaplerosis in these cells is not required; as discussed above, cancer cells can 
find alternative ways to maintain an anaplerotic flux. Continued progress in targeting glutamine 
metabolism for cancer therapy will likely require identification of synergistic drug combinations 
along with careful selection of appropriate target patient groups, which could be aided by new 
techniques for imaging tumor glutamine metabolism in vivo [89-92]. Collectively, recent 
findings on the complexities of cancer cell glutamine metabolism in vivo and ex vivo, far from 
‘completing’ the field, have generated many new questions, and set the scene for future studies 
to provide novel and biologically relevant insights. 
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CHAPTER 2 
 
†Titratable rates of glycolysis quantitatively mediate specific histone acetylation sites 
 
Abstract 
Glucose metabolism links metabolic status to protein acetylation. However, it remains poorly 
understood to what extent do features of glucose metabolism contribute to protein acetylation 
and whether the process can be dynamically and quantitatively regulated by differing rates of 
glycolysis. In this chapter, we show that in HCT-116 human colon cancer cells, titratable rates of 
glycolysis with corresponding changes in the levels of glycolytic intermediates result in a graded 
remodeling of a bulk of the metabolome and resulted in gradual changes in total histone 
acetylation levels. Dynamic histone acetylation levels were found and most strongly correlated 
with acetyl coenzyme A (ac-CoA) levels and inversely associated with the ratio of ac-CoA to 
free CoA. A multiplexed stable isotopic labeling by amino acids in cell culture (SILAC)-based 
proteomics approach revealed that the levels of half of identified histone acetylation sites as well 
as other lysine acylation modifications are tuned by the rate of glycolysis demonstrating that 
glycolytic rate affects specific acylation sites. We demonstrate that histone acylation is directly 
sensed by glucose flux in a titratable, dose-dependent manner that is modulated by glycolytic 
flux and that a possible function of the Warburg Effect, a metabolic state observed in cancers 
with enhanced glucose metabolism, is to confer specific signaling effects on cells. 
                                                
† Adapted from Cluntun, A.A., Huang, H., Dai, L., Liu, X., Zhao, Y. and Locasale, J.W., (2015) Cancer Metab. 3: p. 10. Author 
contributions: A.A.C., Y.Z. and J.W.L designed the study. A.A.C. and J.W.L wrote the paper. A.A.C maintained the cell cultures, 
performed the 2DG treatments, performed the SILAC experiment, collected and analyzed the data, performed the immunoblot 
assays and made all the figures. A.A.C. and X.L performed the metabolomics experiments and ran metabolites on 
HPLC/MS/MS. H.H. and L.D. extracted and digested the histone proteins and performed the PTM purification. Y.Z. advised on 
the acylation proteomics experiments. H.H. ran and analyzed the tryptic peptides.  
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Introduction: 
The metabolism of carbohydrates through glycolysis affects numerous cellular processes through 
its effects on biosynthetic, energy, and reactive oxygen species metabolism. Glucose metabolism 
is altered in pathological conditions such as cancer and autoimmunity[1, 2]. In these cases, cells 
metabolize their glucose under oxygenated conditions, at higher rates, and ferment the glucose to 
produce lactate that together is referred to as the “Warburg effect” or aerobic glycolysis[3]. 
There are many hypotheses for the biological function of the Warburg effect[4, 5]. It has been 
proposed that since glycolysis to lactate occurs at a faster rate than that of oxidative 
phosphorylation, glycolysis provides a means to generate ATP more rapidly[6, 7]. It has also 
been proposed that the Warburg effect is an adaptation to support the biosynthetic requirements 
of cancer cells[8, 9]. Each of these proposals, however, is not without difficulties. For example, 
estimates have found that over 90% of the carbon from glucose is secreted as lactate and alanine 
leaving little room for biosynthesis[10]. Also, the rapid ATP produced by glycolysis can also be 
obtained by other mechanisms such as creatine kinase and adenylate kinase[11, 12].      
Additionally, direct biochemical signaling functions of glucose metabolism are also possible[13, 
14]. When the rate of glycolytic flux changes, it is likely that the levels of metabolites that serve 
as intermediates in glycolysis and associated pathways are consequentially altered. Changes in 
metabolite levels, if they are used as substrates or cofactors for enzymes that carry out 
posttranslational modifications (PTMs), could allow for metabolism to serve an active role in 
remodeling cell physiology by altering signaling activities[15-18]. For example, if these PTMs 
affect the conformation of chromatin, they can potentially alter the expression of thousands of 
genes. Numerous studies have shown that changes in glucose metabolism can regulate histone 
acetylation[19-26]. There are multiple molecular links from glucose metabolism to protein 
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acetylation status including intracellular pH[27]. By this model, pH is mediated by lactate, the 
product of aerobic glycolysis. Acetyl-coenzyme A (ac-CoA), a product of glycolysis, is the 
substrate used by acetyltransferases to modify transfer of the ac-CoA moiety to histones.  In 
addition, the free coenzyme A (CoA) product can inhibit these enzymes[28]. Also, the redox 
status mediated by NAD+ and NADH can affect the activity of certain deacetylases[29].  
Furthermore, ketone bodies, which are produced during fatty acid oxidation, can also 
inhibit histone deacetylases[29, 30]. Despite these intriguing biochemical clues, it remains 
unknown how these phenomena coordinate histone modifications and how they are 
quantitatively mediated. Their specificity regarding defined acetylation sites is also poorly 
understood. In addition, multiple factors can contribute to the regulation of histone acetylation 
resulting from altered glucose metabolism, and identifying the critical factors in metabolism that 
will be important understanding its role in the regulation of histone acetylation. Moreover, 
recently discovered histone modifications such as histone propionylation, butyrylation and 2-
hydroxyisobutyrylation have each been identified as unique histone modifications important for 
gene expression[31-34]. Much like histone acetylation, these modifications use their 
corresponding acyl-CoA metabolite species as substrates for the PTM. How glycolytic flux 
affects the specific pathways that supply the cofactors for these modifications remains unknown. 
Lastly, it remains unclear how coordinated changes in metabolite concentrations at the systems 
level employ altered glucose metabolism to affect biologically important histone acetylation.      
To test the hypothesis that glycolytic rate alters the levels of metabolites that in turn 
regulate histone acetylation, we considered a system where we can quantitatively tune the rate of 
glycolysis and as a result affect the concentrations of metabolites in glycolysis.  We then carried 
out a metabolomics study that considered how differences in metabolite concentrations 
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quantitatively affect histone acetylation. In measuring each potential contribution to histone 
acetylation, we found several factors that contribute to this modification. Together these results 
provide a quantitative model for the contributions of glycolysis to altered histone acetylation and 
acylation and provide evidence for the direct sensing of glucose metabolism by histone 
acetylation. Since histone acetylation controls and in part determines the expression of thousands 
of genes, it is tempting to speculate that this mechanism may provide a general link from 
metabolism to the remodeling of chromatin in cells.  
  
Materials and Methods  
Cell Culture and Reagents. HCT116 colorectal cancer cell lines were cultured in full media 
composed of RPMI 1640, 10% Fetal Bovine Serum (FBS), 100 U/mL penicillin, and 100mg/mL 
streptomycin. All cell lines were obtained as gifts from Lewis Cantley’s laboratory. Cells were 
cultured in a 37 °C, 5% CO2 atmosphere. For 2-Deoxy-d-Glucose (2DG) titration experiments, 
either 2DG (Sigma) was added to the media at the respective concentrations or 0.01% DMSO 
(cellgro) for the Vehicle (Veh). At the start of each experiment cells were seeded at a density of 
2.2 x 106 cells for 10 cm plates for protein collection or 3 x 105 cells/well in a 6-well plate for 
metabolite collection and allowed to adhere and grow to 80% confluence. Cells were then 
washed with PBS and allowed to incubate in the respective treatments for 6 hours. Histones and 
metabolites were extracted as described below. 
 
Immunoblotting. Samples were homogenized in Triton Extraction Buffer (TEB: 0.5% Triton X 
100, 2mM Phenylmethylsulfonyl fluoride (PMSF), 0.02% NaN3 in PBS) and centrifuged at 
2000rpm for 10 min at 4°C. Pellets were resuspended in 0.2N HCl and histones were acid 
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extracted overnight at 4°C. Histones were then precipitated in 100% Trichloroacetic acid (TCA) 
(Sigma-Aldrich), washed with cold Acetone and allowed to air dry. Pellets were either stored at -
20 or dissolved in ddH2O. Histone extracts were loaded onto 12% SDS-PAGE gels and 
transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked in 5% 
dry milk in TBST and incubated with anti-acetyl-H3K27 (Abcam) 1:2000, anti-acetyl H3 
(Millipore) 1:2000, or anti-H3 (Millipore) 1:10000. Horseradish-peroxidase-conjugated anti-
rabbit (Rockland), 1:10,000, was used as secondary antibodies. Chemiluminescent signals were 
detected with Clarity Western ECL Detection Kit (Bio-Rad) and imaged using a ChemiDoc MP 
System (Bio-Rad). 
 
Metabolite Extraction. The procedures for cultured cells are described in previous studies [35, 
36]. Briefly, for culture from adherent cells, the media was quickly aspirated and cells were 
washed with cold PBS on dry ice. Then, 1mL of extraction solvent (80% methanol/water) cooled 
to -80°C was added immediately to each well, and the dishes were transferred to -80°C for 15 
minutes. Plates were removed and cells were scraped into the extraction solvent on dry ice. All 
metabolite extracts were centrifuged at 20,000g at 4°C for 10 min. Finally, the solvent in each 
sample was evaporated in a Speed Vacuum for metabolomics analysis. For polar metabolite 
analysis, the cell extract was dissolved in 15µL water and 15µL methanol/acetonitrile (1:1 v/v) 
(LC-MS optima grade, Thermo Scientific). For nonpolar CoA metabolite analysis, the cell 
extract was dissolved in 50 mM ammonium acetate (pH 6.8). Samples were centrifuged at 
20,000g for 10min at 4°C and the supernatants were transferred to Liquid Chromatography (LC) 
vials. The injection volume for polar metabolite analysis was 8 uL. 
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U-13C-Glucose labeling. Cells were first cultured in standard RPMI 1640, 10% Fetal Bovine 
Serum (FBS), 100 U/mL penicillin, and 100mg/mL streptomycin media to 70% confluence. 
They were then washed with PBS and treated with corresponding 2DG in fresh media as 
described above and incubated for 6 hours. Subsequently, the cells were washed with PBS and 
corresponding media conditions where glucose is replaced with U-13C6-D-glucose (Cambridge 
Isotope Laboratories, Inc.) was considered. Metabolites were then extracted at the indicated time 
points as described in the text from the spent media. 
 
Liquid Chromatography. For polar metabolites an Xbridge amide column (100 x 2.1 mm i.d., 3.5 
µm; Waters) is employed, whereas for nonpolar acyl-CoA metabolites a LUNA C18 column 
(100 x 2.0 mm; phenomenex) is employed on a Dionex (Ultimate 3000 UHPLC) for compound 
separation at room temperature. The mobile phase A is 20 mM ammonium acetate and 15 mM 
ammonium hydroxide in water with 3% acetonitrile, pH 9.0 and mobile phase B is acetonitrile. 
The linear is as gradient as follows: 0 min, 85% B; 1.5 min, 85% B, 5.5 min, 35% B; 10min, 
35% B, 10.5 min, 35% B, 14.5 min, 35% B, 15 min, 85% B, and 20 min, 85% B. The flow rate 
was 0.15 ml/min from 0 to 10 min and 15 to 20 min, and 0.3 ml/min from 10.5 to 14.5 min. All 
solvents are LCMS grade and purchased from Fisher Scientific. 
 
Mass spectrometry. The Q Exactive MS (Thermo Scientific) is equipped with a heated 
electrospray ionization probe (HESI), and the relevant parameters are as listed: evaporation 
temperature, 120 °C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 kV for 
positive mode and 2.5 kV for negative mode. Capillary temperature was set at 320°C, and S-lens 
was 55. A full scan range from 60 to 900 (m/z) was used. The resolution was set at 70,000. The 
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maximum injection time was 200 ms. Automated gain control (AGC) was targeted at 3,000,000 
ions. 
 
Metabolomics and data analysis. Raw data collected from LC-Q Exactive MS is processed on 
Sieve 2.0 (Thermo Scientific). Peak alignment and detection are performed according to the 
protocol described by Thermo Scientific. For a targeted metabolite analysis, the method “peak 
alignment and frame extraction” is applied. An input file of theoretical m/z and detected 
retention time of 263 known metabolites is used for targeted metabolites analysis with data 
collected in positive mode, while a separate input file of 197 metabolites is used for negative 
mode. M/Z width is set at 10 ppm. The output file including detected m/z and relative intensity 
in different samples is obtained after data processing. Quantitation and statistics were calculated 
and visualized with Microsoft Excel, Gene-E and MetaboAnalyst online software. 
Stable Isotope Labeling by Amino acids in Cell culture (SILAC) Experiments. Heavy lysine 
(13C615N2-L-Lysine:2HCL), Medium lysine (4,4,5,5-D4-L-Lysine:2HCL) and RPMI 1640 Media 
for SILAC (minus L-Lysine and L-Arginine) were purchased from Cambridge Isotope 
Laboratories, Inc. Light lysine (L-Lysine HCl) and arginine (L-Arginine HCl) were purchased 
from Amresco. Cells were inoculated into a 6 well plates and allowed to grow for at least 6 
doublings in respective SILAC media. Media was replenished every 3 days. Cells were then 
expanded to 15 cm plates till 80% confluent. Cells were then treated with corresponding 2DG 
treatments (100uM, 5mM, veh) for 6 hours. (5 mM:heavy lysine, 100 µM:medium lysine, 
veh:light lysine).  
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Histone proteins extraction and in-solution digestion. The “heavy”, “medium”, and “light” 
labeled cells were washed twice with pre-chilled PBS, and the core histone proteins were 
prepared using an acid-extraction procedure previously described [37], respectively. Each acid-
extracted histone protein solution was clarified by centrifugation for 10 min at 20,000xg. The 
protein concentrations of the supernatants were measured and equal amounts of proteins from the 
three pools of cells were combined. Then trypsin (Promega Corp., Madison, WI) was added into 
the protein mixtures at a trypsin-to-protein ratio of 1:50 (w/w) for digestion at 37 oC for 16 
hours. 
 
PTM specific immunoaffinity purification (IP). To enrich the peptides with specific PTMs (lysine 
acetylation, lysine propionylation, lysine butyrylation, and lysine 2-hydroxyisobutyrylation), 200 
µg of tryptic peptides were incubated with PTM-specific antibody-immobilized beads 
(containing 20 µg of antibody, PTM Biolabs, Chicago, IL) in NETN buffer (50 mM Tris pH 8.0, 
100 mM NaCl, 1 mM EDTA, 0.5% NP40) at 4 °C for 6 hours with gentle rotation. The beads 
were carefully washed three times with NETN buffer, twice with ETN buffer (50 mM Tris, pH 
8.0, 100 mM NaCl, 1 mM EDTA) and once with ddH2O. After IP, 24.22% (on average) of the 
total identified peptides are modified. The bound peptides were eluted from the beads with 
0.1%TFA in water and vacuum-dried. The resulting peptides were dissolved in 0.5% formic 
acid-water solution, and desalted with Ziptip C18 (EMD Millipore Corp., Darmstadt, Germany) 
according to the manufacturer’s instructions.  
 
HPLC/MS/MS analysis of tryptic peptides. The desalted samples were dissolved in 2.5 µL HPLC 
A buffer containing 0.1% formic acid and 99.9% water (v/v). The solution was directly loaded 
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onto a homemade capillary column (10 cm length with 75 µm inner diameter) packed with 
Jupiter C12 resin (4 µm particle size, 90 Å pore size, Phenomenex Inc., Torrance, CA) and 
connected to a NanoLC-1D plus HPLC system (Eksigent Technologies, LLC., Dublin, CA). 
Peptides were eluted with a gradient of 5% to 90% HPLC buffer B (0.1% formic acid in 
acetonitrile, v/v) in buffer A (0.1% formic acid in water, v/v) at a flow rate of 300 nL/min over 
76 min. The eluted peptides were ionized and introduced into an LTQ-Orbitrap Velos mass 
spectrometer (Thermo Fisher Scientific Inc., Waltham, MA) using a nanospray source. Full MS 
scans were acquired in the Orbitrap mass analyzer over the range m/z 300-1800 with a mass 
resolution of 60000 at m/z 400. The 20 most intense peaks with charge of +2 - +4 were isolated 
for MS/MS analysis. 
 
SILAC based quantification analysis. Protein and PTM site identification and quantification were 
performed with MaxQuant version 1.3.0.5 software [38, 39] against Uniprot human reference 
protein database concatenated with reverse decoy database and protein sequences of common 
contaminants. Trypsin was specified as cleavage enzyme with 2 and 4 max missed cleavages for 
protein and PTM site quantification, respectively. Maximum numbers of labeled amino acids 
were set as 3 and 5 for protein and PTM quantification, respectively. Several variable 
modifications were selected: oxidation (M), acetylation (protein N-term); acetylation (K), tri-
methylation (K), di-methylation (K,R), mono-methylation (K,R), and specific PTM at lysine 
residues corresponding to each immunoaffinity purification. False discovery rate (FDR) 
thresholds for protein, peptide and modification sites were specified at 0.01. Minimum peptide 
length was set at 7 for protein quantification and 5 for PTM site quantification. Identified PTM 
sites with Andromeda score less than 40 or site localization probability less than 0.75, as well as 
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site identifications from reverse or contaminant protein sequences were removed. In addition, C-
terminal modified peptides were also removed unless located at the peptide C-terminal residue of 
the corresponding protein. Protein ratios were determined based on a minimum of two peptide 
ratios using razor and unique peptides. The final PTM site ratios were normalized by their 
protein ratios.  
 
Results  
Development of a system for titratable rates of glucose metabolism 
To investigate quantitative mechanisms linking glucose metabolism to histone acetylation, we 
developed a system where the rates of glucose metabolism and as a result, levels of metabolites 
could be controlled in a precise manner. One possibility of a tunable system is to consider the 
incorporation of 2-deoxyglucose (2DG) into cells (Fig. 2.1A).  2DG can affect glycolysis 
through multiple inhibitory mechanisms. It is taken up in cells via glucose transporters (GLUTs) 
where it is phosphorylated by hexokinase but cannot be further metabolized in glycolysis by 
phosphofructoisomerase[40]. At all concentrations, 2DG directly competes with glucose for 
binding and product inhibition of glucose and glucose-6-phosphate[40-43]. At higher 
concentrations, 2DG acquires the properties of an inhibitor of hexokinase[44-46]. At 
intermediate concentrations, a combination of multiple mechanisms that can affect glycolytic 
rate occur[45, 47]. Thus, differing concentrations of 2DG may exert unique effects on glycolysis 
(Fig. 2.1A). To exploit these different characteristics, we treated cells with 2DG at different 
concentration with short incubation times. The short times were considered in order to minimize 
potential confounding indirect effects of 2DG on cells that occur downstream of glycolysis that 
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may ensue at longer incubation times. Notably, this timeframe is also sufficiently long for 2DG 
to enter cells and initiate its mechanism of action. We therefore treated HCT116 cells with six 
concentrations (0, 0.1, 0.5, 1, 2.5, and 5 mM) of 2DG for a short time (6 hours) that preceded 
growth arrest and any detectable cell death (Fig. 2.1E). A graded accumulation of glucose in the 
extracellular media was observed, as unphosphorylated glucose cannot be retained 
intracellularly[46] (Fig. 2.1B). At these differing concentrations, we next measured the 
phosphorylated product of 2DG, 2-deoxyglucose-6-phosphate (2DG6P), which accumulates in 
the cell since its negative charge precludes it from passing through cell membranes, and also 
observed a dose-dependent accumulation of this product as well[46] (Fig. 2.1C). Furthermore, 
we employed a kinetic flux profiling experiment using U-13C-glucose and observed a decrease in 
the production rate of labeled lactate in the medium, further confirming that the system is 
affecting glycolytic flux directly at differing doses of 2DG treatment (Fig. 2.1D). These results 
indicate that a gradual change in 2DG dose results in similar incremental changes in glycolytic 
flux as well as in the levels of metabolites both in glycolysis and more broadly across the  
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Figure 2.1. The rate of glucose metabolism and extent of metabolic reprogramming can be 
tuned with pharmacological manipulation.  
(A) Schematic of 2DG effects on glycolysis at high vs low concentrations. (B) Relative 
extracellular glucose levels in response to each 2DG concentration compared to the vehicle 
(Veh). (C) Relative 2DG6P levels in response to 2DG treatment compared to Veh. (D) 
Production rate of 13C-labeled lactate in response to 2DG treatment. Fold change in relative 
amounts of lactate in media after respective treatments is depicted. (E) Cell viability test of HCT-
116 cells after 6 hours of growth under indicated treatments. Mean ± SEM of triplicates relative 
to the Veh. (*P <0.05 relative to Veh) 
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metabolic network.  To investigate how this titratable change in glycolysis globally affected 
cellular metabolism, we generated a profile of over 300 metabolites using a metabolomics 
technology we have recently developed based on liquid chromatography coupled to high 
resolution mass spectrometry[35, 36, 48]. This measurement allows for the quantitation of a 
diverse spectrum of metabolic pathways including sugar, amino acid, and polar lipid metabolism. 
Across these different concentrations of 2DG, we observed graded waves of changes in 
metabolism involving multiple different pathways across the metabolic network (Fig. 2.2A). An 
inspection of glycolytic intermediates (Fig. 2.2B) revealed a graded response in the depletion of 
metabolites, whereas, tricarboxylic acid (TCA) cycle (Fig. 2.2C) intermediates displayed a more 
complex response. Pyruvate exhibited a qualitatively different behavior from that of the other 
glycolytic intermediates likely due to other sources including lactate and alanine also 
contributing to pyruvate biosynthesis.  Other substrates such as glutamine and fatty acids are 
anaplerotic carbon sources in the TCA cycle that complicate these observations[9, 10]. Together 
these findings indicate that glycolysis can be gradually tuned with differing levels of 
intermediate metabolites.  
 
The levels of cofactors and substrates that mediate protein acetylation are affected by glycolysis  
Having demonstrated that gradually perturbing the rate of glycolysis results in gradual 
differences across metabolism, we then looked more closely at the metabolic network 
responsible for the levels of metabolites that mediate protein acetylation. Several metabolites 
related to glycolysis and others downstream of glucose metabolism that could affect acetylation 
were investigated. NAD+ is the cofactor for sirtuins that carry out deacetylation reactions.  It has 
also been postulated that sirtuins could be regulated by the NAD+/NADH ratio.   Beta-  
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Figure 2.2. 2DG treatment has a global effect on cellular metabolism.  
(A) Heatmap of effects of 2DG treatment on global metabolism relative to Veh. (B) Effects of 
2DG treatment on glycolytic metabolite levels relative to Veh. (C) Effects of 2DG treatment on 
TCA cycle intermediate levels relative to Veh. Mean ± SEM of triplicates 
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hydroxybutryate (β-OHB), a ketone body, is a functional histone deacetylase (HDAC) 
inhibitor[30]. Also, both ac-CoA levels and the ratio of ac-CoA/CoA have been found to mediate 
acetylation reactions (Fig. 2.3A). Some of these results may be unexpected and differ from what 
has been reported in prior studies that have used manipulations such as glucose deprivation or 
calorie restriction[49]. These previous studies, however, have focused on long-term 
consequences of complete glycolytic inhibition as opposed to acute treatments that identify direct 
biochemical consequences.    
We observed a dose-dependent gradual decrease of intracellular levels of ac-CoA (Fig. 
2.3B) in response to 2DG treatment. We also observed a graded increase in the ac-CoA/CoA 
ratio (Fig. 2.3C). A smaller decrease in overall NAD+ levels was also observed (Fig. 2.3D). The 
Pyr/Lac ratio, which is a surrogate for the cytosolic NAD+/NADH ratio, decreased with 2DG 
treatment; however, this decrease was constant with all treatments (Fig. 2.3E). Both aceto-
acetate, a ketone body, (Fig. 2.3F) and β-OHB (Fig. 2.3G) were unaffected by 2DG treatment. 
Together these results indicate that metabolites known to mediate protein acetylation via lysine 
acetyl transferases (KATs) are sensitive to glycolytic flux, whereas those known to be important 
for HDACs appear to be regulated by other fluxes.  
 
Global histone acetylation levels are determined by glycolytic flux 
Having observed a decrease in metabolites known to be involved in protein acetylation in 
response to 2DG, we next investigated whether there are corresponding changes in histone 
acetylation levels. We first considered whether histone acetylation would respond to glucose 
availability (Fig. 2.4A). We found, consistent with what has been previously described [21, 22, 
49], histone acetylation levels were altered in response to changes in glucose availability. Indeed,  
  49 
 
 
 
 
 
 
 
 
 
Figure 2.3. Glucose metabolism quantitatively alters substrates and co-factors for 
posttranslational modifications.  
(A) Known metabolic pathways that can affect histone acetylation. (B) ac-CoA levels in 
response to 2DG treatments relative to Veh. (C) ac-CoA/CoA ratio in response to 2DG 
treatments relative to Veh. (D) NAD+ levels in response to 2DG treatments relative to Veh. (E) 
Pyruvate/Lactate ratio in response to 2DG treatments relative to Veh. (F) ac-acetate levels in 
response to 2DG treatments relative to Veh. (G) β-hydroxybutyrate levels in response to 2DG 
treatments relative to Veh. Mean ± SEM of triplicates  
 
 
 
 
 
 
 
  50 
 
 
 
 
 
 
 
 
 
  51 
we observe a dose dependent decrease of histone acetylation levels on global acetylated histone 
H3 (ac-H3) levels as well as acetylated histone H3 at residue 27 (H3K27) levels in response to 
2DG treatments (Fig. 2.4B). These decreases had a strong positive correlation with ac-CoA (Fig. 
2.4C), ac-CoA/CoA (Fig. 2.4D), Pyr/Lac (Fig. 4D) and NAD+ levels (Fig. 2.4D). Together these 
results identify the variables in the metabolic network that are associated with ac-CoA and 
illustrate the precise metabolite levels that result from changes in glycolytic flux that are 
important for regulating histone acetylation levels.   
 
Glycolytic flux can affect other histone acylation PTMs  
We so far observed that changes in glycolytic flux induce corresponding changes in 
global acetylation levels and that there exists tight correlations with the levels of key metabolic 
variables and global histone acetylation levels. We next considered whether these changes 
occurred non-specifically across histones or whether specificity could be achieved through this 
mechanism as has been suggested.  
To test this hypothesis, we performed a multiplexed stable isotopic labeling by amino 
acids in cell culture (SILAC) experiment. Such a procedure could determine quantitative changes 
of specific histone acetylation sites that were modulated by glucose. We cultured cells in three 
media conditions containing unlabeled (12C) lysine (light), 4,4,5,5-D4-L-lysine (medium) and, 
13C615N2-L-lysine (heavy). These conditions have been previously shown not to affect growth 
rate and are minimally metabolized in cells[50, 51]. We treated these SILAC-labeled cells with 
0.1 mM (low), or 5mM (high) 2DG and compared them to DMSO (Veh) treated cells  
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Figure 2.4. The rate of glycolysis determines histone acetylation.  
(A) Western Blot of Pan-acetyl-H3 and H3K27ac in response to glucose titration with 
quantification; total H3 was used as loading control. (B) Western Blot of Pan-acetyl-H3 and 
H3K27ac in response to 2DG treatment with quantification; total H3 was used as loading 
control. (C) Scatter-plot depicting correlation between ac-CoA levels and H3K27ac levels. (D) 
Bar graph of Spearman correlation coefficient of ac-CoA:CoA, β-OHB, ac-acetate, ac-CoA, 
CoA, Pyr/Lac and NAD+. Mean ± SEM of triplicates (*P <0.05 versus Veh) 
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(Figure 2.5A). We identified a total of 17 acetylation sites on histones and after hierarchical 
clustering; distinct patterns of response were observed (Fig. 2.5B). Some residues exhibited no 
obvious trend in histone acetylation in response to changing rates of glycolytic flux. Others 
exhibited no change in total acetylation level. However, 7 identified acetylation sites exhibited a 
graded decrease in total levels in response to a decrease in glycolytic flux. Histone residues that 
exhibited this pattern included H3K9ac, H3K14ac, H3K18ac, H4K8ac, H4K12ac, and H4K16ac 
(Fig. 2.5B). After quantifying the differences in the change in acetylation across the three 
different rates of glycolysis, it was found that the levels of about 40 percent (7/17) of the 
acetylation sites changed in a gradual quantitative manner in response to a change in glycolysis 
(Fig. 2.5C). Moreover, these sites were highly correlated to both ac-CoA levels and ac-CoA/CoA 
ratios (Fig 2.5D). Together these data show that manipulating metabolic flux using 2DG 
treatments can have specific effects on individual histone acetylation marks and that these effects 
can be seen at low doses. In addition to acetylation, it has recently come to our attention that 
other lysine acylation modifications occur on histones. These modifications, rather than using ac-
CoA as the substrate, use more chemically elaborate acyl-CoA metabolites as substrates and are 
derived from other parts of intermediary metabolism[52]. Whether they respond to glycolysis 
flux is not known. We therefore considered a further investigation of the extent that glycolysis 
may mediate the levels of other lysine residues. Using the previously developed multiplexed 
SILAC approach, we considered three additional histone lysine modifications, 2-
hydroxyisobutyrylation (Khib) (Fig. 2.6A), butyrylation (Kbu) (Fig. 6B), and propionylation (Kpr) 
(Fig. 2.6C) totaling an additional 32 histone modifications. We found that histone propionylation 
(Kpr) (Fig. 2.6C), histone butyrylation (Kbu) (Fig. 2.6B), and histone 2-hydroxyisobutyrylation  
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Figure 2.5. Quantitative proteomics identifies specific dose-dependent changes in histone 
acetylation.  
(A) Schematic of SILAC experiment workflow. (B) Heatmap of all detected histone acetylated 
residues in response to 2DG treatment. (C) Correlation coefficients of acetylated histones in 
relation to CoA and ac-CoA levels. (D) Quantification of the difference in sensitivity of ac-
Histone residues to 2DG treatment.  
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(Khib) (Fig. 2.6A) levels at all residues were gradually sensitive to glycolytic rate. Unlike lysine 
acetylation (Kac), each of these modifications appeared to quantitatively respond to changes in 
glycolytic flux. Together these findings provide evidence that histone acylation exhibits 
specificity in response to changes in glycolytic rate.  
 
Discussion 
The molecular links between the metabolic state of cells and the status of protein 
acetylation have been intriguing [19, 20, 26, 53]. However, the direct quantitative biochemical 
interactions between metabolic flux, metabolite levels, and levels of protein acetylation have yet 
to be demonstrated. By considering a system that allows for controllable rates of glycolysis, this 
study resulted in a systematic analysis of factors in metabolism that contribute, with specificity, 
to acetylation levels. By considering histone modifications, this allowed for considerations of 
possible links between the metabolic state and cellular epigenetics. We were able to show that 
changes in glycolytic flux can have quantitative effects on global histone acetylation levels. This 
occurred first through changes in glycolytic rate having effects on the levels of metabolites in 
glycolysis and peripheral metabolism. Of all metabolites considered, ac-CoA and the ratio of ac-
CoA to CoA appeared to have the strongest influence on histone acetylation.  
Because most KATs have similar binding affinities to both ac-CoA and CoA, it has been 
suggested that the ac-CoA/CoA ratio may affect KAT activity as CoA can also have an 
inhibitory effect on some KATs[28]. Our findings demonstrate that decreasing glycolytic flux 
can decrease both ac-CoA and free CoA pools and that the regulation of these two pools are 
directly downstream of glycolysis. More importantly, our data suggests that the supply of 
intracellular ac-CoA has a greater effect on histone acetylation than the inhibitory effect of free  
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Figure 2.6. Histone acylation marks are sensitive to the rate of glycolysis.  
(A) 2-hydroxyisobutrylation at H2BK5 in response to 2DG treatment. (B) Detected 
Propionylated histone residues responses to 2DG treatment. (C) Detected Butrylated histone 
residues responses to 2DG treatment. L:Light (Veh), M:Medium (0.1 mM 2DG), H:Heavy (5mM 
2DG). The experiments described above were done by Ahmad Cluntun and He Huang. 
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CoA.  Recently, it has been shown that the selectivity of p300, a histone acetyltransferase, can be 
manipulated by intracellular levels of ac-CoA[54]. Furthermore, work in yeast has shown that 
Gcn5 is important in mediating histone acetylation and is very sensitive to intracellular ac-CoA 
levels as well[19]. Our findings show that many other residues not known to be catalyzed by 
these enzymes are also sensitive to the ac-CoA levels suggesting that such a phenomenon is 
likely pervasive in cells. Interestingly, it has not escaped our attention that modifications located 
close to, or on globular histone domains seem to be more resistant to changes in glycolytic flux, 
whereas those on histone tails seem to be more sensitive suggesting that spatial proximity to the 
metabolic milieu may dictate in part those histone mark that are more dynamic. Moreover, we 
show that other histone acylation modifications are sensitive to glycolytic flux that likely follow 
similar principles.   
Finally, histone Kac, Kpr, Kbu and Khib each appear to be globally regulated by 
glycolytic rate and have all been associated with active gene expression. It has been shown that 
these PTMs utilize corresponding acyl-CoA intermediates. However, it is not known they are all 
connected to glycolysis. From our data we can speculate that the decrease in free CoA restricts 
the ability to form the corresponding acyl-CoAs necessary for these PTMs suggesting some 
possibility of enzymatic activity mediating these reactions. The sensitivity of these PTMs to 
glycolytic flux is unexpected and further investigation is required that includes better 
understanding the chemical reaction mechanisms that mediate these PTMs. Their sensitivity to 
glycolytic flux may add to the increasing evolutionary benefits cancer cells gain from the 
Warburg effect as glycolytic rates are increased in these cells by as much as 200 fold compared 
to normal cells. An exciting recent study has demonstrated that resistance to targeted therapy can 
be driven by elevated nutrient levels[55]. As abnormal metabolism is a recurrent theme in 
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cancer, understanding its effect on chromatin biology may lead to newfound insights into tumor 
cell biology and the interaction between metabolism and gene regulation.  
 
Conclusions 
 Multiple functions of the Warburg effect or the enhanced rate of glycolysis observed in 
tumors and proliferative tissue have been proposed. The most notable function in recent years is that 
the Warburg effect allows for increased biosynthesis [1,8]. This current study provides evidence for 
a new, lesser-appreciated interpretation of the Warburg Effect in that it confers direct signaling 
functions to cells by altering the levels of multiple key metabolites that serve as cofactors and 
substrates for reactions involving important post-translational modifications, notably histone 
acetylation, histone butyrylation, histone propionylation and histone 2-hydroxyisobutryrylation.
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Chapter 3 
 
‡Defining the role of the glutaminase isozyme GLS2 in breast cancer cells 
 
Abstract 
Breast cancer is a heterogeneous disease that can be divided into five subtypes, each of which 
have been shown to be metabolically distinct. This includes differences in glutamine dependency 
between these subtypes. Two genes, GLS and GLS2, code the glutaminase enzyme in mammals. 
Although, the GLS enzyme has been intensely characterized, the GLS2 enzyme remains poorly 
studied. In this chapter, we identify GLS2 as a critical, metabolically active enzyme in breast 
cancer cells, and establish that GLS2 can mediate TCA cycle anaplerosis in these cells. 
Moreover, we establish that breast cancer cell subtypes exhibit distinct expression patterns of 
these two glutaminase enzymes. The small molecule, 968, is an effective inhibitor of both GLS 
and GLS2. We show that treating breast cancer cells with this inhibitor, can decrease 13C-
glutamine labeling of TCA cycle intermediates regardless of GLS or GLS2 expression levels. 
This sheds new light on the metabolic heterogeneity of breast cancer metabolism, and has 
important implications due to the fact that a glutaminase inhibitor, which fails to block GLS2 
activity, is currently in Phase II trials.  
 
                                                
‡This work was done in collaboration with Dr. Michael J. Lukey. Contributions: MJL and AAC designed 
the study, maintained the cell cultures and performed the drug treatment assays, MJL performed all the 
immunoblot assays and created all the knockdowns, AAC wrote this chapter, made all the figures, 
designed and performed all the metabolomics experiments, including running the metabolites on the 
HPLC/MS/MS, as well as collecting and analyzing the data and performed the 968 time course assay. 
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Introduction 
Despite treatment advances, breast cancer remains a leading cause of cancer deaths 
among women worldwide[1]. This may be partially due to the fact that genomic studies have 
established breast cancer as a complex heterogeneous disease that can be divided into five 
intrinsic subtypes (Luminal A, Luminal B, HER2-enriched, Claudin-low, Basal-like) and a 
normal breast-like group[2, 3]. Recently, these subtypes have been shown to be metabolically 
distinct, as luminal breast cancer cells typically exhibit increased glucose uptake, whereas most 
basal breast cancer cells rapidly consume the amino acid glutamine[4].  
Increased uptake of glutamine by cancer cells can help fulfill biosynthetic demands 
associated with proliferation[5], including the requirement for an anaplerotic pathway to 
maintain the tricarboxylic acid (TCA) cycle[6]. Glutamine is unique in its ability to serve as an 
important source of both carbon and nitrogen[6]. Consequently, there has been a growing interest 
in identifying targets to disrupt the ability of cancer cells to utilize this nutrient. One such target 
is the mitochondrial enzyme glutaminase (GLS), which converts glutamine to glutamate.  
In mammalian cells, two genes encode glutaminase enzymes, GLS and GLS2. GLS has 
been intensely studied and currently has a selective inhibitor, CB-839, under evaluation in 
clinical trials for treatment of triple-negative breast cancer and renal cell carcinoma[7]. The GLS 
and GLS2 proteins are highly homologous, and most reports indicate that both are localized to 
mitochondria [8-10]. However, although it is well established that GLS is highly expressed and 
important for growth of several cancer types, there is less clarity on the role of GLS2 in 
tumorigenesis, since it has been reported to be downregulated in liver cancer and 
glioblastoma[11, 12], yet upregulated in neuroblastoma[13], colon cancer[14] and cervical 
cancer[15].  Here, we identify GLS2 as a critical metabolic enzyme in luminal breast cancer 
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cells, and establish that GLS2 mediates TCA cycle anaplerosis in this breast cancer subtype. We 
also demonstrate that the glutaminase inhibitor 968 is an effective inhibitor of both GLS and 
GLS2, in contrast to BPTES and CB-839 which selectively target the GLS isozyme. Moreover, 
we establish that breast cancer cell subtypes exhibit distinct expression patterns of the two 
glutaminase enzymes. This shed new light on the metabolic heterogeneity of breast cancer 
metabolism and may help guide future treatment strategies.  
 
Results 
GLS and GLS2 have distinct expression levels in luminal and basal breast cancer cells 
We initially selected a panel of breast cancer cell lines with varying degrees of glutamine 
dependency, including luminal breast cancer-derived cell lines that can survive and proliferate, 
albeit at a decreased rate, in the absence of exogenous glutamine (T-47D and MCF7), a 
glutamine-dependent luminal breast cancer cell line (MDA-MB-453), and glutamine-dependent 
basal breast cancer-derived cell lines (Hs 578T, MDA-MB-231 and TSE) (Figure 3.1A). To 
confirm the breast cancer cell line subtypes, we performed an immunoblot analysis and used 
GATA binding protein 3 (GATA3) as a marker of luminal breast cancers. We also assessed 
levels of both glutaminase proteins, GLS and GLS2, in these cell lines (Figure 3.1A). All of the 
glutamine-dependent basal cell lines expressed high levels of GLS but very low or undetectable 
levels of GLS2. The luminal cells expressed lower levels of GLS and higher levels of GLS2, and 
MDA-MB-453 cells expressed GLS2 exclusively. Taken together, we confirm that basal and 
luminal breast cancer cell lines have unique GLS and GLS2 expression profiles. 
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Figure 3.1. Basal and luminal breast cancer cell lines have distinct glutaminase isozyme 
expression patterns.  
A. Representative Western blots for GLS and GLS2 levels across a number of breast cancer cell 
lines. All samples were run on the same gel, reorganized here for presentation. B. Heatmap of 
hierarchical clustering of global metabolite levels across all cell lines (HS 578T not shown). 
GATA3: GATA binding protein 3, GLS2: glutaminase 2, GLS: glutaminase, 453: MDA-MB-
453, 231: MDA-MB-231, Lum: Luminal breast cancer cells, Bas: Basal breast cancer cells.  
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Basal and luminal breast cancer cells cluster according to their metabolome 
To investigate the differences between these cell lines in their global metabolic patterns, we 
generated a profile of global metabolites for each cell line using liquid chromatography coupled 
to high-resolution mass spectrometry (LC-MS). Remarkably, a hierarchical clustering of the 
metabolomics data across the cell lines clustered the cell lines into luminal and basal (Figure 
3.1B). Moreover, each of these subtypes display an enrichment of various pathways related to 
glutamine metabolism (Table 4.1). These results confirm that luminal and basal breast cancer 
cells are metabolically distinct. Moreover, irrespective of their dependence on an abundant 
extracellular supply of glutamine, all of these cell lines are enriched in metabolites that are 
related to glutamine metabolism. 
 
Glutamine metabolism can feed the TCA cycle in both basal and luminal breast cancer cells  
Since both subtypes showed an enrichment of glutamine metabolism pathways, we next 
sought to investigate how these cells utilize glutamine. To this end, we performed a stable 13-C 
glutamine tracing experiment. We specifically targeted the TCA cycle intermediates to determine 
whether or not GLS2 can feed this critical pathway in a manner similar to GLS. Indeed, we find 
that glutamine was able to feed the TCA cycle across all cell lines (Figure 3.2B). This includes 
MDA-MB-453 cells, which exclusively express GLS2 and have no detectable levels of GLS. 
None of the cell lines utilized reductive carboxylation, as indicated by the lack of any M+5 
isotopomers of citrate. However, cell lines were grown in normoxic, monolayer cell culture 
conditions, and it is possible that these patterns would be altered under hypoxia or in 3D culture 
conditions. Taken together, we show that breast cancer cell lines that express either GLS or 
GLS2 utilize glutamine metabolism to feed the TCA cycle. 
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Table 4.1. Enriched metabolic pathways according to breast cancer subtype. 
Luminal Breast Cancer Cells Basal Breast Cancer Cells 
Fatty acid biosynthesis 
L-Glutamine and L-glutamate metabolism 
Purine metabolism 
Linoleic acid metabolism 
Alanine, aspartate and glutamate metabolism 
Glycolysis or Gluconeogenesis 
Pyruvate metabolism 
Ala, Asp, Glu metabolism 
Gly, Ser, Thr metabolism 
Aminoacyl-tRNA biosynthesis 
Arg and Pro metabolism 
Val, Leu, Iso biosynthesis 
Nitrogen metabolism 
Arg, Orn metabolism 
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Glutaminase inhibition has variable effects on basal and luminal breast cancer cells 
Having determined that glutamine is feeding the TCA cycle in each of the breast cancer cell 
lines, we next investigated the roles of GLS and GLS2. To achieve this, we treated the cell lines 
with two allosteric inhibitors of glutaminase, bis-2-(5- phenylacetamido-1,2,4-thiadiazol-2-
yl)ethyl sulfide (BPTES) and the benzophenanthridone known as 968. BPTES is a GLS-specific 
inhibitor[16], whereas 968 can inhibit both GLS and GLS2[17-19]. We performed the 
experiments on cells growing in medium containing 13C labeled glutamine. The inhibitors were 
added simultaneously with the labeled media and the cells were left to grow in this media for 10 
hours (see methods of details). We then extracted metabolites from these cells and paid specific 
attention to the TCA cycle intermediates downstream of the glutaminase reaction. We observed a 
significant decrease in the labeling patterns of TCA cycle intermediates downstream of GLS in 
basal breast cancer cell lines in response to BPTES treatment, relative to the untreated vehicle 
cells (Figure 3.3B). We also observed variable degrees of resistance to BPTES treatment in the 
GLS2-expressing luminal breast cancer cell lines (Figure 3.4B). This can be attributed to the fact 
that some GLS is expressed in MCF7 and T-47D cells, in addition to GLS2. MDA-MB-453 
cells, which do not express any GLS and have high levels of GLS2, showed complete resistance 
to the BPTES treatment (Figure 3.4B). It is important to note that all of these TCA cycle 
intermediates have cytosolic pools[10], moreover, there are multiple anaplerotic pathways that 
can supply the TCA cycle beyond glutamine metabolism that can account for the complexity and 
variability in the degree of sensitivity to these inhibitors[6]. After 10 hours treatment, 968 had 
very little effect on any of the cells compared to the vehicle, whereas BPTES treatment had a 
strong effect on cells that express GLS, but little to no effect on cells that expressed GLS2. Later 
in this chapter, we describe experiments designed to assess the effects of more prolonged  
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Figure 3.2. Glutamine can feed TCA cycle anaplerosis in both basal and luminal breast 
cancer cells.  
A. Schematic depicting the incorporation of 13C from glutamine into the TCA cycle. B. Bar 
graphs depicting the abundance ratios of relevant isotopologue species of TCA cycle 
intermediates. Glu: glutamate, α-KG: alpha-ketoglutarate, Succ: succinate, Fum: fumarate, Mal: 
malate, Cit/Iso: citrate-isocitrate. Mean ± SEM of triplicates  
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Figure 3.3. Effects of BPTES and 968 treatments on metabolites downstream of 
glutaminase in basal breast cancer cells.  
A. Schematic depicting the incorporation of 13C from glutamine into the TCA cycle. B. Bar 
graphs depicting abundance ratios of relevant isotopologue species of TCA cycle intermediates 
in BPTES and 968 treated and untreated (vehicle) basal cells. Inhibitors were added at a final 
concentration of 10uM cultured in media containing labeled 13C-Glutmaine for 10 hours.  231: 
MDA-MB-231, Gln: glutamine, Glu: glutamate, α-KG: alpha-ketoglutarate, Succ: succinate, 
Fum: fumarate, Mal: malate, Cit/Iso: citrate-isocitrate. Mean ± SEM of triplicates 
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Figure 3.4. Effects of BPTES and 968 treatments on metabolites downstream of 
glutaminase in luminal breast cancer cells.  
A. Schematic depicting the incorporation of 13C from glutamine into the TCA cycle. B. Bar 
graphs depicting abundance ratios of relevant isotopologue species of TCA cycle intermediates 
in BPTES and 968 treated and untreated (vehicle) luminal cells. Inhibitors were added at a final 
concentration of 10uM cultured in media containing labeled 13C-Glutmaine for 10 hours. 453: 
MDA-MB-453, Gln: glutamine, Glu: glutamate, α-KG: alpha-ketoglutarate, Succ: succinate, 
Fum: fumarate, Mal: malate, Cit/Iso: citrate-isocitrate. Mean ± SEM of triplicates 
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treatment with 968. 
 
GLS2 is an important metabolic enzyme that can feed the TCA cycle 
To investigate the roles of GLS and GLS in breast cancer cells, we next used genetic approaches 
to knockdown levels of these isozymes, and repeated the labeling experiment to detect changes 
in flux into the TCA cycle. We used short hairpin RNAs (shRNAs) to specifically target either 
GLS or GLS2. For both enzymes, we selected the two constructs that gave the most potent 
knockdown (Figure 3.5A, Figure 3.6A). In the basal breast cancer cell lines, MDA-MB-231 and 
TSE, knocking down GLS had a similar effect as BPTES treatment, with a decrease in labeling 
of TCA cycle intermediates observed (Figure 3.5C).  
In the luminal breast cancer cell line MDA-MB-453, which exclusively expresses GLS2, 
knocking down GLS2 levels severely diminished the labeling of TCA cycle intermediates from 
glutamine (Figure 3.6C), thereby confirming GLS2 as a metabolically active enzyme. To our 
knowledge, this is the first report establishing GLS2 as an important enzyme for TCA cycle 
anaplerosis in breast cancer cells. Selective knockdowns of a single isozyme had the most potent 
effects in MDA-MB-231 (GLS) and MDA-MB453 (GLS2) cells, presumably because these cells 
express only one glutaminase isozyme, whereas TSE and T47D cells express both GLS and 
GLS2. Nevertheless, we do still detect decreases in the levels of glutamate, α-ketoglutarate and 
succinate, indicating that it is likely that these cells use both isozymes to varying degrees.   
 
968 can inhibit both GLS and GLS2 
To further investigate the impact of 968 treatment, we exposed cells to 968 for longer incubation 
times. Previous studies have shown that 968 preferentially binds to monomeric glutaminase[17],  
 83 
 
 
 
 
 
 
 
Figure 3.5. Effects of knocking down GLS on metabolites downstream of glutaminase in 
basal breast cancer cells. 
A. Immunoblot depicting the efficacy of the five shRNA constructs in knocking down levels of 
GLS, 48 hours after viral transduction. B. Schematic depicting the incorporation of 13C from 
glutamine into the TCA cycle. C. Bar graphs depicting abundance ratios of relevant isotopologue 
species of TCA cycle intermediates in control shRNA and GLS-targeted shRNA transduced 
basal breast cancer cells cultured in media containing labeled 13C-Glutmaine for 10 hours. 231: 
MDA-MB-231, Gln: glutamine, Glu: glutamate, α-KG: alpha-ketoglutarate, Succ: succinate, 
Fum: fumarate, Mal: malate, Cit-Iso: citrate-isocitrate. Mean ± SEM of triplicates 
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Figure 3.6. Effects of knocking down GLS2 on metabolites downstream of glutaminase in 
luminal breast cancer cells.  
A. Immunoblot depicting the efficacy of the five shRNA constructs in knocking down GLS2 
levels, 48 hours after viral transduction. B. Schematic depicting the incorporation of 13C from 
glutamine into the TCA cycle. C. Bar graphs depicting abundance ratios of relevant isotopologue 
species of TCA cycle intermediates in control shRNA and GLS2-targeted shRNA-transduced 
luminal breast cancer cells cultured in media containing labeled 13C-Glutmaine for 10 hours. 
453: MDA-MB-453, Gln: glutamine, Glu: glutamate, α-KG: alpha-ketoglutarate, Succ: 
succinate, Fum: fumarate, Mal: malate, Cit-Iso: citrate-isocitrate. Mean ± SEM of triplicates 
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Figure 3.7. 968 requires extended incubation times to inhibit GLS2 in MDA-MB-453 cells.  
Bar graphs depicting relative abundance of relevant TCA cycle intermediates in 968-treated 
MDA-MB-453 cells compared to the untreated vehicle cells. Gln: glutamine, Glu: glutamate, α-
KG: alpha-ketoglutarate, Fum: fumarate, Mal: malate, Cit: citrate-isocitrate. Mean ± SEM of 
triplicates 
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Figure 3.8. 968 requires extended incubation times to inhibit GLS in MDA-MB-231 cells.  
Bar graphs depicting relative abundance of relevant TCA cycle intermediates in 968-treated 
MDA-MB-231 cells compared to the untreated vehicle cells. Gln: glutamine, Glu: glutamate, α-
KG: alpha-ketoglutarate, Fum: fumarate, Mal: malate, Cit: citrate-isocitrate. Mean ± SEM of 
triplicates 
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rather than to the catalytically active tetramer species, and it is therefore possible that 968 can 
only effectively target newly-synthesized glutaminase proteins. 
Thus, extended incubation times may allow 968 to bind to newly-synthesized monomers 
before GLS or GLS2 assemble into their quaternary structure. To this end, we carried out a time-
course for 968 treatments on MDA-MB-453 cells (exclusive GLS2 expression) and MDA-MB-
231 cells (exclusive GLS expression). This revealed that, over time, 968 treatment increases in 
potency and effectiveness, leading to decreases in the relative abundances of TCA cycle 
metabolites downstream of the glutaminase reaction in both luminal and basal breast cancer cell 
lines (Figure 3.7, Figure 3.8). Together these results show that 968 can indeed inhibit both GLS 
and GLS2 in monolayer cultured breast cancer cells and that the potency of this inhibition 
increases with time. 
 
Discussion 
Our results reveal that the glutaminase isozyme GLS2 is metabolically active in breast 
cancer cells. Moreover, basal and luminal breast cancer cells have distinct expression profiles of 
both GLS and GLS2. Furthermore, both of these enzymes can feed TCA cycle anaplerosis and 
may be utilized in parallel to varying degrees. These findings have potentially important clinical 
implications since there is a GLS-specific inhibitor, CB-839, currently in Phase II clinical trials 
for treatment of breast cancer. Indeed, our findings may help explain the mixed results thus far 
exhibited by CB-839 in treating breast cancer cells, both in vivo and ex vivo[7].  
The discovery that GLS2 is frequently downregulated in liver cancers, together with early 
work indicating a pro-oncogenic role for GLS, initially led to the proposal that the two isozymes 
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play opposing roles during tumorigenesis. However, more recent findings indicate that in certain 
contexts, GLS2 can be important for tumor progression. For example, a recent loss-of-function 
screen specifically identified GLS2, but not GLS, as one of the top 16 hits of essential metabolic 
genes for tumorigenesis[20]. The confusion surrounding the role of GLS2 may have obscured the 
significance of this finding as it pertains to cancer cell metabolism. One possible explanation for 
the lack of clarity in the field is that while these homologous enzymes do not have fundamentally 
different catalytic roles (i.e. they both convert glutamine into glutamate), they are subject to 
distinct modes of regulation. Indeed, whereas expression of the GLS gene is enhanced by 
oncogenic transcription factors associated with cell-cycle progression [21, 22], transcription of 
GLS2 is driven both by the tumor suppressor p53 in response to oxidative stress [12], and also by 
the proto-oncoprotein N-myc [13]. Disruption of p53 function likely explains some instances of 
downregulated GLS2 expression in tumors. However, there are some intrinsic differences 
between the GLS and GLS2 enzymes that could lead to selective pressure for the former over the 
latter. In the presence of phosphate, GLS has a significantly higher affinity for glutamine than 
does GLS2, resulting in a much higher catalytic efficiency[23]. Furthermore, it was recently 
reported that the distinct GLS2 C-terminus binds to and inhibits the activation of the small 
GTPase Rac1, resulting in suppressed migration, invasion, and metastasis of liver cancer cell 
lines [24].  
A recent report has found that pancreatic cancer cells can utilize compensatory pathways 
to combat glutamine inhibition[25].  In this study, the authors treated pancreatic cancers both in 
vivo and ex vivo with the glutaminase inhibitor CB-839 and observed a decrease in its ability to 
affect glutamine metabolism over time. This decrease was linked to the ability of these cancer 
cells to utilize alternative pathways to synthesize glutamate[25]. In contrast, the 968 treatment 
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experiments described here had the opposite outcome, increasing in potency over time. Further 
work is required to determine if the inhibition observed from the 968 treatments will persist at 
even longer incubation periods. It is tempting to speculate that highly specific inhibitors like CB-
839 may prove to be less effective in treating cancers, as the metabolic network of the cell 
possesses the metabolic plasticity to adapt to this single obstruction to glutamine utilization in 
cancer cells.  
In conclusion, luminal and basal breast cancer cells have distinct expression patterns of 
the glutaminase isozymes GLS and GLS2. We identify GLS2 as an important metabolically 
active enzyme in breast cancer, which can supply the TCA cycle in a similar manner to GLS. 
Finally, we show that 968 requires extended incubation times to improve its efficacy in blocking 
glutamine-mediated anaplerosis. Identifying GLS2 as an active metabolic enzyme in breast 
cancers will add yet another layer of complexity to the metabolic heterogeneity of cancer, and 
may prove to be critical for future improvements in cancer therapies. 
 
Materials and Methods  
Cell Culture and Reagents. MCF7, T-47D, MDA-MB-453, MDA-MB-231, TSE and Hs 578T 
breast cancer cell lines were cultured in full media composed of RPMI 1640, 10% Fetal Bovine 
Serum (FBS). Cells were cultured in a 37 °C, 5% CO2 atmosphere. BPTES and 968 (10 uM, 
final concentration) were added to the media or 0.01% DMSO (cellgro), which represents the 
vehicle control (Veh). At the start of each experiment, cells were seeded at a density of 2.2 x 106 
cells for 10 cm plates for protein collection or 3 x 105 cells/well in a 6-well plate for metabolite 
collection and allowed to adhere and grow to 80% confluence. Cells were then washed with PBS 
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and allowed to incubate in the respective treatments for 10 hours. Metabolites were extracted as 
described below. 
 
Immunoblotting. Whole-cell lysates were prepared in lysis buffer (50 mM HEPES pH 8.0, 150 
mM NaCl, 1 mM Na3VO4, 25 mM NaF, 1% (v/v) Triton X-100, 1 mM MgCl2, 50 mM β-
glycerophosphate, 30 µg ml−1 leupeptin, 5 µg ml−1 aprotinin) and insoluble debris was pelleted 
by centrifugation and removed. Protein concentration was determined by Bradford assay (Bio-
Rad), and lysate proteins denatured by boiling for 5 min in reducing SDS-sample buffer. Lysate 
proteins (20 µg total protein/lane) were then resolved on Novex 4–20% Tris-glycine mini or midi 
protein gels (Life Technologies), and transferred to polyvinylidene difluoride membranes 
(PerkinElmer). Membranes were blocked in 7% bovine serum albumin in tris-buffered saline and 
tween 20 (TBST) for 1 h at room temperature, and probed overnight at 4 °C in primary antibody 
solution in TBST. They were then washed in TBST, and incubated in TBST solution containing 
25% (v/v) non-fat dry milk powder and appropriate secondary antibody at the manufacturer's 
recommended concentration for 1 h. Finally, the membranes were washed in TBST, and bands 
imaged using Western Lightning Plus-ECL (PerkinElmer) and HyBlot ES autoradiography film 
(Denville Scientific Inc.).incubated with anti-GLS antibody is Abgent AP8809b at 1:8000, and 
GLS2 antibody is Abcam ab113509 at 1:5000. The latter recognizes GLS as well, so samples 
have to be run on a 12% gel to separate the GLS and GLS2 bands. 
 
 
Metabolite Extraction. The procedures for cultured cells are described in previous studies [26, 
27]. Briefly, for adherent cells, the media was quickly aspirated and cells were washed with cold 
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PBS on dry ice. Then, 1 mL of extraction solvent (80% methanol/water) cooled to -80°C was 
added immediately to each well, and the dishes were transferred to -80°C for 15 minutes. Plates 
were removed and cells were scraped into the extraction solvent on dry ice. All metabolite 
extracts were centrifuged at 20,000g at 4°C for 10 min. Finally, the solvent in each sample was 
evaporated in a Speed Vacuum for metabolomics analysis. For polar metabolite analysis, the cell 
extracts were dissolved in 15µL water and 15µL methanol/acetonitrile (1:1 v/v) (LC-MS optima 
grade, Thermo Scientific). Samples were centrifuged at 20,000g for 10 min at 4°C and the 
supernatants were transferred to Liquid Chromatography (LC) vials. The injection volume for 
polar metabolite analysis was 8 uL. 
 
U-13C-Glutamine labeling. Cells were first cultured in standard RPMI 1640, 10% Fetal Bovine 
Serum (FBS) media to 70% confluence. They were then washed with PBS and treated with the 
corresponding drug treatments or vehicle in media conditions where glutamine is replaced with 
U-13-C6-L-glutamine (Cambridge Isotope Laboratories, Inc.) for 10 hours. Metabolites were 
then extracted as described in the text from the cells and the media.  
 
Liquid Chromatography. An Xbridge amide column (100 x 2.1 mm i.d., 3.5 µm; Waters) was 
employed on a Dionex (Ultimate 3000 UHPLC) for compound separation at room temperature. 
The mobile phase A was 20 mM ammonium acetate and 15 mM ammonium hydroxide in water 
with 3% acetonitrile, pH 9.0, and the mobile phase B was acetonitrile. The linear gradient is as 
follows: 0 min, 85% B; 1.5 min, 85% B, 5.5 min, 35% B; 10 min, 35% B, 10.5 min, 35% B, 14.5 
min, 35% B, 15 min, 85% B, and 20 min, 85% B. The flow rate was 0.15 ml/min from 0 to 10 
min and 15 to 20 min, and 0.3 ml/min from 10.5 to 14.5 min. All solvents are LCMS grade and 
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purchased from Fisher Scientific. 
 
Mass spectrometry. The Q Exactive MS (Thermo Scientific) is equipped with a heated 
electrospray ionization probe (HESI), and the relevant parameters are as listed: evaporation 
temperature, 120 °C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 kV for 
positive mode and 2.5 kV for negative mode. Capillary temperature was set at 320°C, and S-lens 
was 55. A full scan range from 60 to 900 (m/z) was used. The resolution was set at 70,000. The 
maximum injection time was 200 ms. Automated gain control (AGC) was targeted at 3,000,000 
ions. 
 
Metabolomics and data analysis. Raw data collected from LC-Q Exactive MS was processed on 
Sieve 2.0 (Thermo Scientific). Peak alignment and detection were performed according to the 
protocol described by Thermo Scientific. For a targeted metabolite analysis, the method “peak 
alignment and frame extraction” was applied. An input file of theoretical m/z and detected 
retention time of 204 known metabolites was used for targeted metabolites analysis with data 
collected in positive mode, while a separate input file of 278 metabolites was used for negative 
mode. M/Z width is set at 10 ppm. The output file including detected m/z and relative intensity 
in different samples is obtained after data processing. Quantitation and statistics were calculated 
and visualized with Microsoft Excel, MORPHEUS and MetaboAnalyst online software. 
 
GLS and GLS2 Knockdowns 
For knockdown of GLS or GLS2, cells were grown in RPMI 1640, 10% FBS media until 70% 
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confluent, and then transduced with lentiviruses containing MISSION shRNA constructs 
(Sigma) targeting human GLS or GLS2, or a non-targeting control shRNA construct, in the 
presence of polybrene, for 48 hours. 
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Chapter 4 
Conclusions and future directions 
Conclusions 
The discovery that glucose was the main source of acetyl groups found on acetylated 
histones, and that these groups could appear on histone tails within a time period of minutes[1, 
2], prompted us to wonder if there was a connection between the increased glycolytic rates 
observed in cancer cells due to the Warburg effect and histone acetylation patterns. Indeed, the 
work described in Chapter 2 provides evidence for an unappreciated consequence of the 
Warburg effect, whereby it carries out signaling functions in cells by altering the levels of 
multiple key metabolites that serve as cofactors and substrates for reactions involving histone 
acetylation. Of all metabolites considered in this study, ac-CoA, and the ratio of ac-CoA to CoA, 
appeared to have the strongest influence on histone acetylation (Figure 2.4.C, D).  
Recent work has shown that intracellular ac-CoA levels could manipulate certain 
acetyltransferases such as p300 and Gcn5[3, 4]. In our study we identified many other residues 
not known to be catalyzed by these enzymes are also sensitive to the ac-CoA levels, suggesting 
that such acetylation events are likely pervasive in cells. Additionally, we found that the 
locations of these modifications on histones seemed to influence their sensitivity to changes in 
glycolytic flux, thus suggesting that spatial proximity to the metabolic milieu may dictate, in 
part, histone modifications that are more dynamic. We also identified other histone acylation 
marks that were sensitive to glycolytic flux, notably, histone butyrylation, histone propionylation 
and histone 2-hydroxyisobutryrylation (Figure 2.6.). The sensitivity of these posttranslational 
modifications (PTMs) to glycolytic flux was unexpected and further investigation is required 
which would benefit from a better understanding of the chemical reaction mechanisms that 
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mediate these PTMs. Their sensitivity to glycolytic flux may add to the adaptive responses that 
cancer cells derive from the Warburg effect as glycolytic rates are increased in these cells by as 
much as 200 fold compared to normal cells. An exciting recent study has demonstrated that 
resistance to targeted therapy can be driven by elevated nutrient levels[5]. As abnormal 
metabolism is a recurrent theme in cancer, understanding its effect on chromatin biology may 
lead to new insights into tumor cell biology and the interactions between metabolism and gene 
regulation.  
Additionally, the 2DG system we developed to manipulate glycolytic flux, beyond being 
an effective research tool, may have many interesting implications. First, we show that treating 
cells with low doses of this inhibitor for short time periods can decrease glycolytic flux without 
completely obstructing it.  The implication here is that changes in dose and incubation times may 
have drastic effects on the effectiveness of therapies targeting metabolic pathways. It is tempting 
to speculate that this may be an underlying reason for the mixed results obtained with 2DG in 
cancer therapy[6]. Indeed, recent work on glutaminase inhibitors[7], as well as our studies with 
968 described in Chapter 3, supports this notion. Given the strong connections between 
metabolism and epigenetics[8], I would go as far as to recommend that any drug treatment that 
targets a metabolic pathway, should also be assessed for its effects on the epigenome, before any 
conclusions can be made regarding its effectiveness as a therapy.  
 
 Glutaminase has long been thought to be an important enzyme for cancer cell 
survival. However, most of the attention in the field has been given almost exclusively to GLS 
and not to its isozyme GLS2. Our finding that GLS2 is a metabolically active enzyme that can 
feed TCA cycle anaplerosis in breast cancer cells in a similar manner to GLS may help change 
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this trend. With the increasing appreciation of the heterogeneity of glutamine dependency across 
different cancer types, this finding serves as yet another aspect that may help explain this 
plasticity. Moreover, we show that luminal and basal breast cancer cells have distinct expression 
patterns of the glutaminase isozymes GLS and GLS2. As most studies characterizing breast 
cancers have traditionally been genomic in nature, our findings suggest that the distinct 
metabolic nature of these subtypes may be in part due to unique isozyme utilization. This point 
may prove to be critical for treatment, as drugs that inhibit specific isozymes will be ineffective. 
Following this line of reasoning, we show that the glutaminase allosteric inhibitor 968 can inhibit 
both GLS and GLS2, but requires longer incubation times than BPTES-like inhibitors to realize 
its efficacy in blocking glutamine-mediated anaplerosis.  
The significance of identifying GLS2 as a metabolically active enzyme cannot be 
overstated, as many recent studies would have benefitted from this finding. For example, a recent 
study caused significant confusion and controversy when the authors knocked out GLS in non-
small lung carcinomas (NSCLC), both in cell culture and in vivo, and saw no deleterious effect 
on these tumors[9]. Many people took these findings to mean that glutamine metabolism is an 
artifact of cell culture and that cells grown in live animals do not require it. However, it now 
appears that these cancer types highly express GLS2 but little if any GLS. Moreover, these cells 
express pyruvate carboxylase (PC) that can also feed TCA cycle anaplerosis. The fact that none 
of the reviewers of this paper caught this, or asked the authors to knockdown GLS2, speaks 
volumes about how the field views the importance of GLS2. Also, pancreatic adenocarcinoma 
cells (PDACs) are also known to express GLS2[10], yet this was not considered in the design of 
the recent study that revealed the GLS-specific inhibitor CB-839 lost its efficacy over extended 
incubation times[7]. Unfortunately, the list of studies that ignore GLS2 is extensive, perhaps in 
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part because of the conflicting ideas that have been put forward regarding the role of GLS2 in 
cancer progression. It is my hope that the work described in Chapter 3 of this thesis will help 
shed new light on how GLS2 contributes to certain types of cancer.  
 
Future directions 
The studies presented in this dissertation point to multiple areas worthy of further 
investigation. From the work presented in Chapter 2, I was able to identify specific histone 
acylation marks that change in response to glutamine flux. The next logical step would be to 
perform chromatin immunoprecipitation combined with a massively parallel DNA sequencing 
(ChIP-seq) experiment on these specific marks to identify those genes that are enriched at these 
specific marks. To simplify the experiment, I would perform these studies on cells treated with 
low (0.5 mM) and high (5 mM) concentrations of 2DG,  and compare the results with those 
obtained for the DMSO-treated vehicle. A dynamic change from hyper- to hypo-acylation in 
response to glycolytic flux localized at specific genes would increase the biological relevance of 
our study. Furthermore, I would accompany this experiment with an RNA-seq or RT-PCR 
experiment to confirm that these specific changes in histone acylation marks are affecting the 
transcription of the underlying genes to which they are localized. This could potentially help 
develop a useful model whereby cancer cells utilize the Warburg effect to regulate and maintain 
the expression of specific genes to give these cells a tumorigenic advantage.  
It is important to note that some of the histone modifications identified by our study have 
no known function and it would therefore be very interesting to link any of them to controlling 
gene expression. Moreover, the link between glycolysis and the corresponding acyl-CoA 
intermediates that are presumably acting as acyl-donors for the identified histone marks is still 
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unclear. Although, we assume that this connection may be due the decrease in free CoA, it would 
be interesting to perform an untargeted metabolomics experiment to identify other less obvious 
connections that may also exist. It has become increasingly clear that cancer metabolism can be 
affected by the microenvironment of the cell, thus it would be important to determine if our 
results persist in the context of 3D-cultured cells and in vivo studies.  
Lastly, it will also be of interest to extend this study to a panel of cancer and normal cells, 
that exhibit varying degrees of the Warburg effect (i.e. different rates of glucose consumption) 
and determine if this is reflected in changes in specific histone acylation marks. Finally, the 
compartmentalization of cellular metabolism is an important aspect that is often ignored due to 
the lack of reliable methods to obtain organelle-specific metabolites. However, there have been 
recent improvements and advances in harvesting mitochondrial metabolites, and it would be 
interesting to utilize these techniques to determine if the observed changes in ac-CoA levels are 
happening in the cytosol or the mitochondria. This would be especially interesting when 
considering the many acyl-CoA intermediates.  
The work presented in Chapter 3 serves as a starting point to study GLS2 in cancer. A 
logical follow up to the 13C-labeling experiment would be to perform a labeled 15N-glutamine 
tracing experiment on our panel of breast cancer cells. Since both of these enzymes are thought 
to be catalytically identical, any differences in the observed labeling would be of interest, since 
there are no studies documenting the two isozymes in this manner.  Obviously, extending our 
studies to cells grown in 3D culture and in vivo mouse studies will further our findings and 
potentially uncover metabolic differences due to changes in the tumor microenvironment. It will 
be interesting to determine if these different cell growth conditions result in utilizing either of 
these enzymes preferentially according to changes in the microenvironment of the cells.    
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Still, another interesting experiment would be to determine where exactly does GLS2 
localize within the mitochondria, and if it differs from GLS in this respect. Moreover, it will be 
important to see where else these isozymes localize in cells. Following up on the 968 results will 
also be of great importance. Increasing the incubation times can determine if these breast cancer 
cells ever adapt to these treatments. It will also be interesting to see if 968 behaves in a similar 
manner when cells are grown in 3D culture or in mice. Finally, extending these studies to 
determine how active GLS2 is in other cancer types beyond the breast cancer lines used in 
Chapter 3 will be very important. Lung and pancreatic cancer derived cells would be good 
subjects of study to determine if GLS2 can explain the observed heterogeneity in glutamine 
dependency that has been observed in these cells. 
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Glossary 
 
Anaplerosis: The process of replenishing metabolic pathway intermediates. For example, carbon 
that is lost from the TCA cycle to supply biosynthetic reactions can be replenished by glutamine-
derived α-KG, glucose-derived oxaloacetate, etc. 
Auxotroph: an organism that is unable to synthesize a particular compound required for its 
growth. 
Catabolism: Describes metabolic pathways that breakdown macromolecules into smaller units 
and release energy. As opposed to Anabolism, which describes energy-consuming biosynthetic 
metabolic pathways that construct macromolecules to build biomass of the cell. 
Epigenetics: The study of heritable changes in gene expression that does not involve changes to 
the underlying DNA sequence. Often encompassing chemical modifications to the DNA and 
Histones.  
Extracellular Vesicles: Bilayered membrane-enclosed packages that are shed by various cell 
types including cancer cells and can contain important cargo that facilitates paracrine signaling. 
These vesicles can be divided into two broad classes according to size and the unique underlying 
mechanisms of their biogenesis. A large vesicle class with a diameter of 0.2-1 um called 
microvesicles, which are plasma membrane-derived and result from its budding and fission. And 
a much smaller class with a diameter of 0.04 to 0.1 um known as exosomes, that are derived 
from multi-vesicular bodies that reroute and fuse to the plasma membrane for exocytosis[147-
149]. 
ex vivo: taking place outside of a living organism with minimal deviation from natural 
conditions.  
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Glutaminolysis: The metabolic breakdown of glutamine. 
Immunometabolism: The changes in intracellular metabolic pathways in immune cells that alter 
their function.  
in vivo: taking place in a living organism  
Macropinocytosis: A regulated actin-dependent form of endocytosis, which enables the cell to 
engulf extracellular macromolecules such as proteins.  
Warburg Effect: Also known as aerobic glycolysis, is the phenomenon of increased glucose 
uptake coupled to lactate secretion, regardless of O2 availability in cancer cells.  
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Appendix  
Complementary Data 
 
 
Table A.1.1. List of detected histone modifications and their sensitivity to glycolytic flux 
Histone Residue Modification Domain Glucose Sensitivity 
H3K9 Ac, Bu Tail + 
H3K14 Ac, Bu Tail + 
H3K18 Ac, Bu Tail + 
H3K23 Ac, Pr, Bu Tail + 
H3K56 Ac Tail - 
H3K79 Ac Globular - 
H4K5 Ac, Pr, Bu Tail + 
H4K8 Ac, Pr, Bu Tail + 
H4K12 Ac, Pr, Bu Tail + 
H4K31 Ac Globular - 
H2AK5 Ac, Bu Tail + 
H2BK5 Ac, Bu, Hib Tail + 
H2BK15 Ac, Bu Tail + 
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H2BK16 Ac, Bu Tail + 
H2BK20 Ac, Bu Tail + 
H2BK108 Ac Tail - 
 
